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ABSTRACT 
 
The carcinogenic events leading to urinary bladder and kidney malignancy 
are incompletely understood. This study examined protein expression of potential 
biomarkers in cancers of the urinary bladder and kidney, utilizing the tissue 
microarray (TMA) technique, which is a novel high-throughput tool for molecular 
studies of cancer. 
The results indicate that urinary bladder tumors display distinct expression 
profiles for the actin-associated proteins gelsolin and E-cadherin. Gelsolin and E-
cadherin expression was decreased in premalignant and malignant lesions, when 
compared with that of benign samples. With an increase in tumor grade and stage, 
however, gelsolin expression increased, unlike E-cadherin expression. An 
increased gelsolin expression in high-grade bladder tumors was associated with an 
increased risk for progression and recurrence. Expression of biomarkers p53 and 
Ki-67 increased from the level in benign lesions to levels in malignant lesions, and 
then rose with increasing tumor grade. Additionally, genomic amplification in 
chromosomal region 8q24 occurred in a subgroup of predominantly high-grade 
bladder tumors and in a more significant group of distant metastases. That the 
tumors and distant metastases carrying the 8q24 amplification over-expressed Ki-
67 supports the hypothesis that 8q24 amplification contributes to these tumors’ 
malignant potential. None of the regional lymph node metastases carried 8q24 
amplification. 
Renal tumors having sarcomatoid features were studied for the expression 
of tissue biomarkers Ki-67, gelsolin, and PTEN, and compared with that in clear-
cell and papillary tumors. The distinct expression profiles in all these tumor types 
support the hypothesis that in the development of renal malignancies various 
molecular pathways are involved. Gelsolin expression in clear-cell and sarcomatoid 
tumors was low, but high in papillary tumors, which suggests that gelsolin may 
play multiple roles within these renal tumor types. A more detailed analysis of the 
most common renal malignancy, renal clear-cell carcinoma, revealed that Ki-67 
expression independently predicts prognosis. Additionally, simultaneous increased 
Ki-67 expression and diminished gelsolin expression may indicate poor prognosis 
in grade 2 tumors. The most significant predictor of cancer-specific survival in 
renal clear-cell carcinoma was, however, tumor stage. 
In summary, this study shows that urinary tract tumors have distinct 
biomarker expression profiles. The results also indicate, in cancers of the urinary 
bladder and kidney, that these expression profiles may be used to predict prognosis. 
Additionally, that gelsolin expression was transiently down-regulated in these 
cancer types suggests that gelsolin may play multiple roles in the development of 
urinary tract cancer and its progression. These results demonstrate that the TMA 
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technique effectively facilitates study of urinary tract malignancies and provides an 
opportunity for multimarker analysis in discovery-based cancer profiling. 
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REVIEW OF THE LITERATURE 
 
High-throughput techniques in cancer research 
 
Cancer development involves multiple genetic and epigenetic alterations in 
those cells undergoing malignant transformation (Hanahan and Weinberg 2000). 
Until recently, cancer research has mainly progressed through studies of one or 
only a very few molecules, events, or samples at a time. Sequencing of the human 
genome (International Human Genome Sequencing Consortium 2001; Venter et al. 
2001) and the simultaneous rapid development of high-throughput techniques for 
the study of cellular events has had an enormous impact on cancer research (Weber 
2002). For example, promising results have come from microarray techniques to 
classify breast cancer and lymphoma more accurately according to their molecular 
status (Perou et al. 2000; Garcia et al. 2002). These new techniques enable a global 
discovery-based approach to events leading to cancer and may provide a more 
comprehensive view of the carcinogenic process. These novel techniques are also 
useful in target identification, pinpointing the molecules and pathways essential to 
cancer development. At the other end of the spectrum, the amount of novel 
information is sufficiently large to allow for the recognition of molecular 
relationships at organism level. It is likely that such discovery-based approaches 
will become the frontiers of cancer research, enabling the identification of truly 
new, unpredicted findings (Lee 2001). 
Systematic analysis of the carcinogenic events – oncogenomics – can be 
performed combining data from several different sources. Several novel laboratory 
methods – cDNA expression arrays, oligonucleotide arrays, comparative genomic 
hybridization (CGH), TMAs, protein arrays, cell arrays, and single cell arrays  – 
facilitate studies of various aspects of cancer, ranging from the expression of a 
single gene to complex cell dynamics (Schena et al. 1995; Sapolsky and Lipshutz 
1996; Kallioniemi et al. 1992; Kononen et al. 1998; Madoz-Gurpide et al. 2001; 
Ziauddin and Sabatini 2001; Levsky et al. 2002) . 
 
Tissue microarrays 
 
Traditionally, tissue-level protein expression in cancer has been studied in 
one tumor, or a few tumors, at one time. Immunohistochemical (IHC) methods can 
be time-consuming, with inter-experimental variability in the results, due to 
variability in staining conditions. Costs of such experiments can be high, especially 
with a large number of tissues. Thus, novel methods free of these limitations 
should accelerate discovery in studies of large numbers of tumors for protein 
expression (Kononen et al. 1998). 
  
12
The multitumor tissue block introduced in 1986 was one of the first steps in 
the development of a more efficient technique for IHC studies of protein 
expression (Battifora 1986). This tissue block was designed to permit economical 
and rapid screening for tissue-specific monoclonal antibodies and simultaneous 
selection of those antibodies that perform well in tissue sections. Assessment of 
protein expression in individual samples was, however, impossible. The 
checkerboard tissue block, which was developed a few years after the multitumor 
tissue block, allowed the study of up to one hundred tissue samples in a single 
experiment, simultaneously allowing evaluation of each individual sample 
(Battifora and Mehta 1990). It was designed to permit rapid and inexpensive 
screening of new histologic reagents, thus facilitating intra- and interlaboratory 
quality control, and was mainly designed to answer questions regarding reagents, 
not regarding the tissue samples themselves. 
The most important step thus far in the development of high-throughput 
techniques for tissue-level molecular pathology studies was the development of the 
tissue microarray (TMA) technique by Kallioniemi and colleagues (Kononen et al. 
1998). The TMA technique allows protein-expression studies of hundreds of 
individual tissue samples in a single experiment, while allowing several – up to 200 
– consecutive experiments on the same set of samples with different antibodies. 
Furthermore, the TMA technique also enables DNA- and RNA-level studies of the 
same TMA blocks used for protein expression analyses. Compared to traditional 
methods, TMA experiments save costs, time, and precious archived tissue samples. 
TMA and cDNA techniques are complementary high-throughput techniques; TMA 
is applicable to targeted population screening (1 gene / 1000 tissues), whereas the 
cDNA microarray is applicable to genome screening (1 tissue / 5000 genes). 
 
 
Figure 1. TMA construction. 
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Construction of TMAs 
Construction of TMAs is a multistep process. The part requiring the most 
time and efforts in the construction of TMA is the search, organization, 
pathological review, and processing of the specimens to be included in the array 
(Kallioniemi et al. 2001). After the formalin-fixed, paraffin-embedded original 
specimens have been selected and reviewed by the pathologist, core biopsies – 
usually 0.6 mm in diameter – are taken from areas representing the desired 
morphology, be it normal-appearing, dysplastic, or malignant, and then inserted 
into a TMA block. The sufficient number and qualities of cores taken per sample 
has been a question of debate. Cores selected should reflect the properties of the 
whole tissue without compromising rapid analyses. Since the degree of 
heterogeneity varies between tumor types, the number of cores required depends on 
tissue type (Gillett et al. 2000). TMA validation studies for cancer tissues show that 
the optimal number of cores to capture reliably the heterogeneity of tumors varies 
from three in breast to four in prostate cancer (Camp et al. 2000; Rubin et al. 
2002). In bladder cancer, correlations between clinicopathological parameters and 
Ki-67 antibody expression in a whole-tissue analysis can be accurately reproduced 
with TMA. The TMA technique can also be applied to studies of heterogeneous 
tumors, e.g., lymphomas (Garcia et al. 2002). Despite some discrepancies between 
matched whole-tissue and TMA samples, overall results are strikingly similar 
(Nocito et al. 2001). TMA construction, illustrated in Figure 1, is a straightforward 
process in a technical sense. Existing TMAs have been constructed by use of a 
manual first-generation arrayer (Kononen et al. 1998). Once the TMA block has 
been finished, thin – usually 5 µm – sections are cut by microtome to generate 
TMA slides for molecular analyses (Figure 2). An adhesive-coated tape-sectioning 
system serves to keep the orientation of the tissue spots intact. 
 
Detection of targets on TMA slides 
DNA-level TMA studies utilize a fluorescence in situ hybridization (FISH) 
technique. This technique was first introduced in 1969, when radioactive labels 
were the standard (Gall and Pardue 1969). An in situ hybridization technique based 
on fluorescent labeling was introduced in 1986 (Pinkel et al. 1986), and FISH was 
used to detect chromosomal aberrations in bladder cancer for the first time in 1989 
(Hopman et al. 1989). FISH has been successfully applied in studies of 
amplifications of defined genomic regions in several types of cancers (Richter et al. 
2000; Kallioniemi et al. 2001; Simon et al. 2001; Simon et al. 2002). The 
hybridization procedure has been improved since the introduction of the TMA 
technique, in order to address the challenge of varying hybridization properties 
between individual samples on a single slide (Andersen et al. 2001). 
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Figure 2. Urothelial cancer tissue microarray slide stained with hematoxylin and eosin. 
Original magnification: x1, x20 and x100 (top to bottom). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The TMA analysis of mRNA expression is performed with labeled 
oligodeoxynucleotide probes recognizing mRNA (Kononen et al. 1998). 
Investigations of mRNA expression using TMAs have limitations, however, due to 
the unpredictable degree of degradation of the RNA before and during the paraffin 
process (Hoos and Cordon-Cardo 2001). 
TMA analyses of protein expression are performed by standard IHC 
methods (Kononen et al. 1998). Conditions for IHC analyses on TMA slides need, 
however, to be adjusted, due to the adhesive that remains on the final TMA slide. 
Variation in staining conditions is small within the samples on a single slide. 
Moreover, slides from several different TMA blocks can be stained simultaneously 
for the selected antibody, reducing the variation created by staining at different 
time-points. When consecutive sections of a TMA block are analyzed, variation in 
the morphological features of the individual samples is small, allowing reliable 
comparison of several molecular targets in practically identical, well-defined 
regions of the tissues (Kallioniemi et al. 2001). Analysis of the stained TMA slides 
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is performed by a trained researcher using a regular light microscope, following the 
guidelines for IHC analyses of the tissue type on the slide. Histological verification 
of each core is usually by a hematoxylin and eosin staining, and is repeated after a 
certain number of slides, e.g., once for every 40 slides (Kononen et al. 1998). 
 
TMA technique in cancer research 
 Most studies utilizing the TMA technique concern human cancer; several 
focus on the expression of cancer-related proteins as well as on potentially cancer-
related proteins in a large number of arrayed tumors (breast, prostate, bladder, 
kidney) (Bubendorf et al. 1999a; Bärlund et al. 2000; Kallioniemi et al. 2001; 
Nocito et al. 2001; Schraml et al. 2001). Many of these studies have shown the 
ability of TMA to serve as a large-scale screening tool for the expression of 
proteins involved in carcinogenesis. The initial studies for each tumor type also 
serve to validate the unique TMA-related characteristics of an individual cancer 
type. These studies thus establish a standardized manner of conducting TMA work 
on a given cancer, so that analyses of their results reveal the properties of the whole 
tumor as closely as possible and allow comparison of the results of different studies 
(Bubendorf et al. 1999a; Camp et al. 2000; Richter et al. 2000; Sallinen et al. 2000; 
Chung et al. 2001; Hoos et al. 2001; Schraml et al. 2001; Hedvat et al. 2002; Sugita 
et al. 2002). 
A potentially effective means of validating new tissue biomarkers of cancer 
is the combination of cDNA microarrays and TMAs. In this two-phase strategy, the 
first phase would involve the use of cDNA microarrays to identify genes whose 
expression differs in cancer tissues from that of normal tissues. The second phase 
would involve investigating the expression of protein products of genes identified 
in the first stage (Mohr et al. 2002). This method can reveal genes and their protein 
products involved in malignant processes and improve prognostic methods. This is 
exemplified by the fact that hereditary breast cancers exhibit distinct gene and 
protein expression profiles (Hedenfalk et al. 2001). In these studies fully exploiting 
the efficiency of TMA as a screening and validation tool, molecular information is 
analyzed together with comprehensive clinical data (Manley et al. 2001). Once the 
often laborious process to set up the TMA and clinical database is completed, 
comparing biomarker expression to parameters already in the database will then be 
rapid. A recent report combined oligonucleotide and tissue microarrays in a study 
of lung carcinoma (Sugita et al. 2002). Another application of this strategy to 
discover novel biomarkers combined CGH, cDNA microarrays, and TMAs, and 
showed that elongin C is a potential target gene of amplification at chromosomal 
region 8q in prostate cancer (Porkka et al. 2002); the advantage of this approach is 
that larger genome-level changes at defined locations can be taken into account in 
interpreting cDNA microarray results, and the additional information provided by 
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CGH can further guide the selection of proteins to be validated by TMA. Perhaps 
the most effective way to validate TMA findings prior to clinical research is 
functional validation: a recent report showed that EZH2 protein expression 
increases during tumor progression in prostate cancer, allowing the repressor effect 
of EZH2 on a specific cohort of genes to be studied at cellular level. This led to the 
conclusion that suppression of gene expression by EZH2 may be essential for a 
tumor to acquire metastatic potential, and that EZH2 may serve to evaluate which 
prostate tumors are most likely to progress (Varambally et al. 2002). 
Thus far, the TMA technique has mainly been used in research settings. 
Clinical applications also have been proposed, however. TMA can serve as an 
internal quality control for antibody staining, if a small array is stained 
simultaneously – and on the same slide – with a whole-tissue sample being 
analyzed for clinical purposes (Packeisen et al. 2002). TMA can also serve as a tool 
for inter-laboratory quality control; staining conditions and interpretation of the 
results can be standardized, which should have obvious benefits for clinical patient 
care (Parker et al. 2002). 
 
Limitations 
The TMA technique was introduced as a rapid screening method enabling 
studies of tumors at DNA, RNA, and protein level (Kononen et al. 1998). Thus far, 
the majority of TMA studies have investigated protein-level events, whereas DNA- 
and RNA-level studies have been rare. Optimization of the FISH technique for 
TMAs can be challenging, due to autofluorescence and weak hybridization; this 
has been the greatest restraint in DNA-level analysis (Andersen et al. 2001). RNA-
level TMA studies suffer from the unpredictable degree of degradation of RNA 
molecules before and during the paraffin process (Hoos and Cordon-Cardo 2001). 
A problem frequently encountered in TMA studies is that spots are often missing 
on the slide, because the cores are not always of the same length and not always 
oriented at a similar depth in the TMA block (Hoos and Cordon-Cardo 2001). To 
overcome this, more than one thin core from the tumor area can be piled on top of 
another in the tissue array (Hoos and Cordon-Cardo 2001). Furthermore, results 
from the TMA technique, accurate as they may be at population level, cannot be 
extrapolated to describe the molecular pathology of any individual tumor, due to 
the small amount of tumor mass in the array and the heterogeneity of the tumor. 
For example, the sample may not come from a representative area of the tumor, or 
in the tumor the heterogeneous areas may be unevenly located (Nocito et al. 2001). 
Another point is that the assessment of protein-level events alone does not provide 
a comprehensive view of each tumor’s biology (Ginestier et al. 2002). Further 
setting limits to applicability of the TMA technique, the resolution of traditional 
IHC methods used in TMA may not always be sufficiently accurate to capture 
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subtle differences in protein expression. This drawback can at least partially be 
reduced by staining methods such as quantitative fluorescence image analysis 
(QFIA) that are capable of capturing quantitative differences in an individual 
protein’s expression more accurately (Rao et al. 2002). 
The TMA technique is essentially a tool for retrospective studies. 
Molecular analyses can be reliably performed for archived formalin-fixed paraffin-
embedded samples dating back at least 60 years (Camp et al. 2000). TMA results 
should, however, be verified in large prospective studies analyzing whole-tissue 
samples before any results are applied clinically (Torhorst et al. 2001). 
 
Tumor profiling 
 
Traditionally, potential biomarkers for cancer have been investigated one 
biomarker at a time. With recent developments in laboratory methods, classifying 
tumors more precisely according to their molecular status has become more 
feasible. A recent report showed that breast tumors can be classified into distinct 
subclasses based on gene expression profiles (Perou et al. 2000). Furthermore, 
these subclasses were later shown to have clinical implications, since outcomes 
differed among subclasses (Sorlie et al. 2001). Another study examined the 
expression profiles of several cell cycle-regulatory and proliferation markers in 
early-stage rectal adenocarcinomas utilizing TMAs; this study demonstrated that 
down-regulation of the p27 protein expression may be associated with survival, 
while other markers (p53, Mdm2, Ki-67) show no association with recurrence or 
survival (Hoos et al. 2002). Similarly, distinct prognostic subgroups of renal clear-
cell carcinoma have been described by cDNA microarrays (Takahashi et al. 2001). 
Perhaps somewhat ironically, despite all the technical developments in 
biomedicine, the traditional evaluation of tumor behavior by grade and stage still 
remains the most applicable in day-to-day clinical decision processes. Emerging 
techniques, however, hold great promise, illustrated by reports describing gene-
expression profiles and validating biomarkers in breast cancer based on cDNA 
microarrays and TMAs (Perou et al. 2000; Hedenfalk et al. 2001). It is likely that in 
the near future, extensive basic research assisted by high-throughput oncogenomics 
will lead to discoveries of biomarkers having clinical use jointly with existing 
methods such as grade and stage. Molecular classification of tumors may in many 
cancers eventually replace or at least supplement traditional methods. Thus far, 
however, classification schemes based solely on molecular phenotypes have not 
been introduced to clinical practice, for several reasons such as lack of prospective 
randomized studies, lack of standardization of laboratory methods, and most 
importantly, lack of specific treatment options for individual molecular phenotypes 
(Ring and Ross 2002). As soon as specific treatments with well-characterized 
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effects and molecular targets become available, selection of treatment for an 
individual patient ultimately may be based on the tumor’s molecular phenotype. 
The current applications of molecular phenotyping, such as defining adjuvant 
treatment for breast cancer on the basis of estrogen receptor and c-erbB2 status of 
the tumor, have shown the usefulness of this molecular approach (Mohr et al. 
2002). 
 
Biomarkers 
 
An optimal tumor marker for cancer would be specific, sensitive, easy to 
interpret, and applicable to the general population. Thus far, the only tumor marker 
widely used in urological practice is the prostate-specific antigen (PSA), used for 
the detection and follow-up of prostate cancer (Takeuchi et al. 1983; Killian et al. 
1985; Van Brussel and Mickisch 1999a). Many of such potential biomarkers are 
encoded by oncogenes (Ras, c-erbB2) or tumor suppressor genes (p53, 
retinoblastoma); functions of the biomarkers are often related to cell cycle control 
(p53, retinoblastoma), cell proliferation (Ki-67), or cell adhesion (E-cadherin) 
(Byrne et al. 2001; Knowles 2001). 
The various biological properties of urinary bladder cancer create special 
requirements for a marker for diagnostic, prognostic, or follow-up purposes. Low-
grade bladder cancer is often a chronic recurrent illness that rarely progresses, 
whereas high-grade bladder cancer can be a notorious disease progressing rapidly 
to a non-curable state. Thus, a marker for bladder cancer would optimally identify 
cancer and make a distinction between these two prognostically different entities. 
Additionally, since the urinary bladder is an organ cystoscopically easily accessed 
and biopsied, a good bladder cancer marker is difficult to find, if we are to exceed 
the high specificity and sensitivity of cystoscopy and bladder biopsy (Van Brussel 
and Mickisch 1999b; Droller 2002). 
Renal cancer is often non-curable at the time of diagnosis, due to its ability 
to remain symptomless while progressing to an advanced stage at which treatment 
options are very limited. A tumor marker capable of detecting renal malignancy at 
an early stage would therefore be potentially life-saving (Van Brussel and 
Mickisch 1999b). 
The simultaneous study of several aspects of carcinogenesis in these tumors 
could aid in characterizing the carcinogenic process, which is incompletely 
understood in cancers of the urinary bladder and kidney. 
 
Actin-associated proteins 
Mutations or reversible defects in actin-associated proteins such as E-
cadherin have been associated with many malignancies. These molecules may act 
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as both tumor suppressors and invasion suppressors (Nollet et al. 1999). Alterations 
in actin cytoskeleton remodeling have been associated with various aspects of 
urothelial carcinoma carcinogenesis, including cellular differentiation (Rao et al. 
1990), transformation (Rao et al. 1991; Rao et al. 1993), and apoptotic control (Rao 
et al. 1999). Monitoring changes in actin polymerization status may provide a 
means of predicting tumor recurrence (Hemstreet et al. 1999). Because the 
cytoskeletal actin network is also crucial to cell motility and adhesion, it has long 
been assumed that alterations in the actin network may also be involved in tumor 
invasiveness. Studying several actin-associated proteins (c-erbB2, vinculin, 
gelsolin) involved in different aspects of actin function simultaneously in actual 
tumor samples may improve our overall understanding of how actin is involved in 
the carcinogenic process. It may also determine whether an actin-based molecular 
profiling analysis can supplement traditional histopathological markers (tumor 
grade and stage) in predicting tumor properties such as tumor invasion and 
recurrence (Feldner and Brandt 2002; Rao 2002). 
 
Gelsolin 
Gelsolin, a well-characterized member of the actin-binding protein family, 
is linked to the carcinogenesis of several organs such as the bladder, prostate, 
breast, and lung (Tanaka et al. 1995; Lee et al. 1999; Shieh et al. 1999; Thor et al. 
2001; Winston et al. 2001). In normal human cells, gelsolin is involved in dynamic 
changes in the actin cytoskeleton, thus affecting cell motility. A major actin 
regulatory protein, it is involved in regulating the actin polymerization process by 
severing and capping F-actin, the polymerized filamentous form of actin 
(Kwiatkowski 1999). It also has functions related to signaling pathways and 
apoptosis. Mutations in the gelsolin gene, located at chromosomal region 9q33, 
cause familial amyloidosis (Finnish type), an autosomal dominant form of familial 
amyloid polyneuropathy (Levy et al. 1990; O'Brien et al. 1993). Familial 
amyloidosis (Finnish type) is a slowly progressing disorder leading to the 
accumulation of amyloid protein in several organs. Despite mutation in the gelsolin 
gene, the patients are at no increased risk for developing malignant tumors (Kiuru 
1992). In the normal human adult kidney, gelsolin is widely expressed in the distal 
tubules and collecting ducts (Lueck et al. 1998). During carcinogenesis, both up- 
and down-regulation of gelsolin occurs in a number of solid tumor types 
(Kwiatkowski 1999). Most reports have shown a decreased expression of gelsolin 
in solid tumors, suggesting a tumor-suppressive role in malignancies of the prostate 
and breast (Tanaka et al. 1995; Lee et al. 1999; Winston et al. 2001). In contrast, 
up-regulation and a negative effect on prognosis have been reported in breast 
cancer and non-small-cell lung cancer (Shieh et al. 1999; Thor et al. 2001). A 
recent in vivo study of a highly metastatic murine melanoma cell line suggested a 
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metastasis-suppressive function for gelsolin (Fujita et al. 2001). The mechanisms 
by which gelsolin exerts its function in cancer development are still uncertain. In 
vitro studies suggest that loss of gelsolin expression plays a critical role in 
urothelial carcinogenesis in cell lines, because the introduction of authentic 
gelsolin cDNA into a human bladder cancer cell line reduces its colony-forming 
ability and tumorigenicity (Tanaka et al. 1995). Furthermore, gelsolin is also 
involved in the regulation of cellular apoptotic processes by functioning as a 
candidate for caspase activity (Kothakota et al. 1997). When adenovirus-mediated 
gelsolin gene therapy was attempted in nude mice with orthotopic bladder cancer, 
tumor size in the gelsolin treatment group decreased markedly (Sazawa et al. 
2002). 
A recent in vitro study showed that invasion induced by gelsolin is 
dependent on Ras activity, establishing a connection between gelsolin and the Ras 
oncogenic signaling pathway (DeCorte et al. 2002). When cancer cells are treated 
with Compound 2, a novel potential therapy for human cancer based on inhibition 
of deacetylases, gelsolin expression increases (Fournel et al. 2002). These findings 
further support the assumption that gelsolin is a carefully regulated downstream 
target of carcinogenic events. 
 
E-cadherin 
E-cadherin is an actin-binding protein belonging to the cadherin family of 
transmembrane glycoproteins, which are the prime mediators of intercellular 
adhesion (Behrens et al. 1989). It mediates the selective adhesion of epithelial cells 
and is required for the interaction and maintenance of normal epithelial integrity 
(Takeichi 1991). Loss of E-cadherin expression leads to dissociation of cells from 
cohesive tissues and, in a variety of solid tumors, generates de-differentiation and 
invasiveness, demonstrating the role of E-cadherin as a suppressor of tumor 
invasion and metastasis (Frixen et al. 1991; Vleminckx et al. 1991). Although a 
number of studies have observed decreased E-cadherin expression in patients with 
urothelial and renal carcinoma, the independent clinical value of E-cadherin 
immunostaining is controversial (Bornman et al. 2001; Shariat et al. 2001; 
Shimazui et al. 1997; Fischer et al. 1999; Nakopoulou et al. 2000; Popov et al. 
2000). Furthermore, a broad clinical survey showed E-cadherin to be transiently 
downregulated in prostate cancer, and to be strongly expressed in hormone-
refractory and metastatic prostatic tumors (Rubin et al. 2001). 
 
Markers of proliferation 
An inherent characteristic of malignant tumors, cell proliferation, can be 
measured by a variety of methods. Mitotic indices widely serve as an element of 
various tumor grading methods. Cell proliferation can be measured by specifically 
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assaying enzymes involved in DNA synthesis, such as thymidine-kinase. 
Immunohistochemical determination of proliferation indices is an expanding area 
of research, based on detection of antigens present during cell proliferation; the 
widely used Ki-67 now has been replaced by the MIB-1 antibody, which has a 
similar epitope selectivity but recognizes its target also in paraffin-embedded 
tissues. No consensus exists as to the best proliferation index, or as to the optimal 
methodology, reagents, or data interpretation. Flow cytometry is widely used, but 
MIB-1 assays are increasingly popular because of their minimal tissue 
requirements and suitability for routinely fixed tissues (Spyratos et al. 2002). 
 
Ki-67 
Ki-67 is a large protein with an established structure. It has a complex 
localization pattern within the cell nucleus and undergoes phosphorylation and 
dephosphorylation during mitosis. Regulation of Ki-67 seems to be tightly 
controlled. Despite the vast amount of information on Ki-67, its function is still 
unclear. Ki-67 is vital for cell proliferation, since removal of Ki-67 protein 
prevents proliferation. Because its protein structure is unique, its function cannot 
be elucidated by comparison with the structure of other proteins (Brown and Gatter 
2002). Ki-67, present in all cycling human cells and a marker of active cell 
proliferation, can identify cells in the proliferating pool (G1, S, and G2 phases) of 
human tumor cells, a fact which has been widely documented for a variety of 
tumors (Elias 1997). IHC staining of Ki-67 (MIB-1) provides an index that 
estimates the growth fraction of a population of cells. Increased Ki-67 expression 
indicates active cell proliferation. The diagnostic and prognostic potential of Ki-67 
protein expression has been studied in cancers of organs such as breast, lung, brain, 
prostate, bladder, and kidney (Brown and Gatter 2002). The labeling indices of Ki-
67 correlate with grade and clinical outcome in bladder cancer and renal cell 
carcinoma (RCC), and provide additional prognostic indication of biological 
aggressiveness (Jochum et al. 1996; Pfister et al. 1999; Rioux-Leclercq et al. 2000). 
While some studies indicate that Ki-67 expression level is an independent 
prognostic factor in RCC, others suggest that Ki-67 expression does not contribute 
additional prognostic information unless incorporated into a prognostic index with 
other factors (Hofmockel et al. 1995; Aaltomaa et al. 1997; Gelb et al. 1997). 
 
Tumor suppressor proteins 
For development and growth of multicellular organisms, regulation of cell 
survival and cell death is essential. The induction or inhibition of cell death is 
fundamental to shaping and organizing tissues during development and for 
permitting adult organisms to respond to and survive environmental stresses that 
are not overwhelmingly damaging to normal cell function. The balance between 
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signals that promote or impair cell survival defines tissue homeostasis and may 
underlie aging and diverse pathologies. Inappropriate loss of cells can lead to 
degenerative diseases and autoimmune disorders, whereas failure to eliminate 
mutated cells that have escaped the constraints of normal growth regulation can 
lead to cancer. Thus, to ensure quality control within cells and ensure the 
organism’s viability, life and death signals work in coordination (Mayo and Donner 
2002). Several tumor-suppressor proteins have been linked to the carcinogenesis of 
urothelial carcinoma and RCC (VHL, fumarate hydratase, retinoblastoma 1, p53) 
(Zambrano et al. 1999; Knowles 2001; Tomlinson et al. 2002). 
 
p53 and PTEN 
The p53 and PTEN tumor suppressors are functionally linked (Mayo and 
Donner 2002); p53, a short-lived, non-abundant protein in normal cells, plays a 
major role in regulating the response of mammalian cells to stress and damage, in 
part through the transcriptional activation of genes involved in cell-cycle control, 
DNA repair, senescence, angiogenesis, and apoptosis. Disruption of any of these 
processes can allow cells to escape from normal growth constraints such as 
apoptosis, allowing passage of mutations from one cell generation to the next, 
which may permit the development of cancer. In approximately half of all cancers, 
the p53 gene is mutated. Its prognostic significance has been evaluated in 
numerous cancers (breast, colon, lung, bladder, kidney) (Soussi and Beroud 2001). 
The PTEN tumor-suppressor protein is a dual-specificity phosphatase. It 
functions as a tumor suppressor by inhibiting activation of PtdIns3-kinase and its 
downstream target, Akt. Mutations of PTEN have been described in cancers of 
several organs such as brain, breast, prostate, and kidney (Li et al. 1997; Steck et 
al. 1997). PTEN and p53, together with the oncoprotein Mdm2, form a tumor 
suppressor-oncoprotein network. The capacity of PTEN to inhibit PtdIns3-kinase-
Akt signaling allows it to block nuclear entry of Mdm2. Recent observations 
confirm this supposition and additionally show that Mdm2, when restricted to the 
cytoplasm, is degraded. Expression of PTEN in PTEN-null glioblastoma cells 
increases the expression of p53 target genes, including those associated with cell 
cycle arrest. PTEN thus protects p53 from survival signals emanating from growth-
factor receptors by inhibition of PtdIns3-kinase-Akt signaling and nuclear entry of 
Mdm2. Demonstration of this PTEN-p53 connection establishes the fact that tumor 
suppressors need not function individually. Rather, tumor suppressors, growth 
signaling pathways, and oncoproteins are networked, and the function of these 
growth inhibitory/growth stimulatory networks is essential for homeostasis. These 
observations also suggest that, during the progression of cancer, loss or mutation of 
one tumor suppressor can undermine the function of another (Mayo and Donner 
2002). 
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Urinary bladder cancer 
 
Overview 
Urothelial carcinoma, or transitional cell carcinoma (TCC), is the most 
common cancer type of the lower urinary tract. More than 57,000 new cases and 
12,000 deaths are predicted for the United States in the year 2003, with the 
incidence of TCC in the United States remaining stable (Jemal et al. 2003). In 
Finland, 900 new cases are predicted in the year 2003 (Finnish Cancer Registry 
2003). Like other malignant neoplasms, urothelial carcinoma develops through 
multiple genetic and epigenetic changes that lead to alterations in growth, 
differentiation, and apoptotic control (Brandau and Böhle 2001). These tumors 
provide a useful model system to study carcinogenic processes, because they have 
a well-defined progression of disease: from premalignant dysplasia to preinvasive 
carcinoma in situ (CIS), to superficial carcinoma, and, finally to invasive 
carcinoma. In addition, it is relatively easy to access the entire organ system 
through urine cytologic and cystoscopic examination (Droller 2002). TCC is a 
unique tumor type. Morphologically, low-grade papillary tumors, which are 
predominantly noninvasive at the time of initial presentation, have a high 
recurrence rate, with over two-thirds of them recurring. In addition, high-grade 
tumors are more invasive at initial presentation, although not all high-grade tumors 
are initially invasive (Jordan et al. 1987). Because tumor grade alone may fail to 
predict the behavior of an individual tumor, additional biomarkers that can predict 
tumor recurrence and the invasive behavior will be useful clinically. 
Several predisposing factors have been identified for TCC. Among the 
most common are exposure to aromatic amines and other chemical carcinogens 
through tobacco use or industrial exposure. Genetic factors contribute to the 
carcinogenesis of sporadic bladder cancer, although the majority of patients with 
TCC have no family history of TCC of the urinary tract. No TCC-causing 
syndromes have been described (Kiemeney and Schoenberg 1996). Cystoscopy and 
urine cytology are the current standard diagnostic methods, and molecular genetic 
methods and several potential bladder tumor tests may assist in its diagnosis. The 
current treatment options are surgery, immunotherapy, and chemotherapy. No 
chemoprevention exists; however, several promising molecules such as cyclo-
oxygenase 2 inhibitors are under investigation (Patton et al. 2002). The prognosis 
of patients with bladder TCC is rather favorable, with the 5-year cancer-specific 
survival being over 70% (Finnish Cancer Registry 2003). 
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Pathological classification 
TCC is by far the most common histologic variant of bladder cancer, 
accounting for approximately 90% of cases. The next most common histologic 
variants are squamous cell carcinoma and adenocarcinoma, at 7% and 2% (Izawa 
and Grossman 2000). Urothelial cancers develop along two biologically distinct 
pathways – low-grade superficial papillary and high-grade flat CIS – with different 
clinical prognoses (Patton et al. 2002). TNM classification from 1997 is used for 
bladder cancer staging (Table 1), with the World Health Organization classification 
currently used for tumor grading (Table 2) (Mostofi et al. 1973; Sobin et al. 1997; 
Cheng and Bostwick 2000). 
 
Pathophysiology 
Various carcinogens and risk factors contribute to the generation of bladder 
carcinomas: beta-naphthylamine, a compound of cigarette smoke, is a well-known 
carcinogen, and smokers have a 4-fold risk for developing urothelial carcinoma. 
An elevated incidence of urothelial carcinomas also appears among workers in the 
rubber industry who are heavily exposed to beta-naphthylamine and other amines 
(Clavel et al. 1989; Vineis and Pirastu 1997). 
In bladder cancer, as in most types of cancer, the transformation of a 
normal into a malignant cell involves a multistep mechanism. Sequentially, the 
expression of various classes of genes – oncogenes, tumor-suppressor genes, cell-
cycle genes, and DNA-repair genes – is altered. These alterations involve 
mutations or chromosomal aberrations such as translocation, insertion, 
amplification, and deletion (Brandau and Böhle 2001). Ras, c-erbB2, and 
epidermal growth factor receptor (EGFR) are among the oncogenes characterized 
in TCC inducing carcinogenesis through activation mechanisms, whereas the 
retinoblastoma gene and p53 are among the tumor-suppressor genes involved in 
bladder carcinogenesis (Brandau and Böhle 2001). 
Bladder cancer shows frequent chromosomal alterations. The most frequent 
gains are in chromosomal regions 1q21-q24, 8q21-q22, and 17q, whereas the most 
common deletions are in chromosomal regions 11p15-p14, 8pter-p22, 9pter-p21, 
and 9q (Simon et al. 2000). Loss of heterozygosity (LOH) also occurs in bladder 
cancer, contributing to carcinogenesis through inactivation of tumor-suppressor 
genes such as p53 (Brandau and Böhle 2001). 
 
Markers associated with bladder malignancies 
Current pathological and clinical parameters such as TNM classification 
provide essential prognostic information yet still have limited ability to predict the 
true malignant potential of most bladder tumors. In the recent years, investigation 
of basic mechanisms involved in carcinogenesis and tumor progression by  
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Table 1. TNM staging system for bladder cancer (Sobin et al. 1997). 
 
Primary Tumor (T) 
TX Primary tumor cannot be assessed 
T0 No evidence of primary tumor 
Ta Noninvasive papillary carcinoma 
Tis Carcinoma in situ: “flat tumor” 
T1 Tumor invades subepithelial connective tissue 
T2 Tumor invades muscle 
    T2a       Tumor invades superficial muscle (inner half) 
    T2b       Tumor invades deep muscle (outer half) 
T3 Tumor invades perivesical tissue 
    T3a       microscopically 
    T3b       macroscopically (extravesical mass) 
T4 Tumor invades any of the following: prostate, uterus, vagina, pelvic wall, 
abdominal wall 
    T4a       Tumor invades prostate, uterus, vagina 
    T4b       Tumor invades pelvic wall, abdominal wall 
 
Regional Lymph Nodes (N) 
 
NX Regional lymph nodes cannot be assessed 
N0 No regional lymph node metastasis 
N1 Metastasis in a single lymph node, 2 cm or less in greatest dimension 
N2 Metastasis in a single lymph node, more than 2 cm but not more than 5 cm in 
greatest dimension, or multiple lymph nodes, none more than 5 cm in greatest 
dimension 
N3 Metastasis in a lymph node more than 5 cm in greatest dimension 
 
Distant metastasis (M) 
 
MX Distant metastasis cannot be assessed 
M0 No distant metastasis 
M1 Distant metastasis 
 
 
Table 2. Histologic grading of papillary urothelial carcinoma (Mostofi et al. 1973). 
Grade 1 Well differentiated 
Grade 2 Moderately differentiated 
Grade 3 Poorly differentiated / undifferentiated 
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molecular biology has provided a host of tumor markers of potential diagnostic or 
prognostic value for bladder carcinoma (Tiguert et al. 2002). These markers may 
serve as tools for early and accurate prediction of tumor recurrence and 
progression, and for development of metastases and prediction of response to 
therapy. Precise prediction of tumor behavior would facilitate treatment selection 
of patients who may benefit from various treatments including surgery and 
adjuvant therapy. Currently, no single marker is able accurately to predict the 
clinical course of bladder tumors and thus to serve as a reliable prognostic marker. 
A combination of prognostic markers could predict which superficial tumors 
require an aggressive form of therapy. Several urine and serum tests have been 
developed in the attempt to discover a marker useful for the detection or 
prognostication of bladder cancer. Despite these numerous research efforts, no 
diagnostic marker with a specificity and sensitivity comparable to cystoscopy 
currently exists. Some of the potential tissue markers of bladder cancer are listed in 
Table 3, among the most promising being Ki-67 and p53 (Kausch and Böhle 2001; 
Kausch and Böhle 2002). 
 
Marker 
 
Biological function Potential prognostic value 
ABO Blood group antigen Diagnostic marker, association 
with progression 
Ras, c-MYC, c-erbB2 Oncogenes Prognosticators of disease 
recurrence (Ras) or survival (c-
erbB2), correlation with tumor 
grade (c-erbB2, c-MYC) or 
metastasis (c-erbB2) 
Rb, p53 Cell cycle regulators Correlation with progression and 
survival (Rb), marker of 
progression, or recurrence and 
survival (p53) 
Ki-67, PCNA Proliferation-associated 
antigens 
Marker of recurrence, 
progression, and survival (Ki-67), 
correlation with tumor grade 
(PCNA) 
E-cadherin Cell adhesion molecule Association with metastasis, 
tumor grade, stage, and survival 
VEGF Peptide growth factor Correlation with tumor stage, 
grade, and recurrence 
EGFR Growth factor receptor Correlation with recurrence and 
progression 
 
Table 3. Tissue markers of bladder cancer (Kausch and Böhle 2002). 
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Renal cell carcinoma 
 
Overview 
RCC is, in the US, the fourteenth leading cause of cancer mortality, with 
32,000 new cases and 12,000 deaths predicted in 2003 (Jemal et al. 2003). 
Incidence has been increasing in the United States during the last 20 years (Tsui et 
al. 2000). In Finland, 800 new cases are predicted in the year 2003 (Finnish Cancer 
Registry 2003). One-third of patients have metastatic disease at diagnosis; 
approximately 50% of those undergoing surgical resection for less advanced 
disease eventually relapse (Bui et al. 2001). The 5-year cancer-specific survival of 
kidney cancer is 60% (Finnish Cancer Registry 2003). Several predisposing factors 
include cigarette smoking, obesity, and hypertension. Genetic factors contribute to 
the carcinogenesis of sporadic kidney cancer, and some inherited syndromes 
predispose to kidney cancer (Godley and Kim 2002). 
For RCC, the best available prognostic indicator is stage, but the current 
prognostic factors: grade, and performance status, as well as stage, are insufficient 
in predicting patient outcome and cancer aggressiveness (Rioux-Leclercq et al. 
2000; Tsui et al. 2000; Pantuck et al. 2001; Zhou and Rubin 2001; Zisman et al. 
2001). Identification of biomarkers that provide further prognostic information 
would thus be vital for defining optimal treatment and outcomes (Elias 1997). 
Before the availability and widespread use of abdominal ultrasonography and 
computerized tomography, the usual presentations of renal lesions were symptoms 
and/or signs of urinary tract pathology.  Now, due to the improved imaging 
techniques and their good availability, renal masses are most frequently incidental 
findings (Nicol 2000). Therapeutic options for renal cancer are surgery and 
systemic therapy. Thus far, for localized kidney cancer nephrectomy is the 
treatment of choice. For advanced kidney cancer, cytotoxic chemotherapy has been 
disappointing, but immunotherapy has remained the mainstay of treatment. The 
most commonly used immunotherapeutic agents are interleukin-2 and interferon-
alpha (Godley and Kim 2002). Cytotoxic agents such as vinblastine have also been 
used in advanced RCC in combination with immunotherapeutic agents (Pyrhönen 
et al. 1999). Gene therapy for RCC is under investigation (Pulkkanen et al. 2001; 
Haviv et al. 2002). Attempts to create more accurate staging systems for RCC 
include integration of molecular and clinical information into the system along 
with the current prognostic factors (Pantuck et al. 2001; Zisman et al. 2001). 
 
Pathological classification 
The UICC/AJCC classification of RCC serves to classify it, with 
morphological and genetic facts integrated (Table 4) (Storkel et al. 1997; Pantuck 
et al. 2001). Sarcomatoid differentiation appears in all RCC subtypes, and when  
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Table 4. UICC/AJCC classification of renal cell carcinoma (Sobin et al. 1997). 
 
Benign neoplasms 
 Papillary adenoma 
 Renal oncocytoma 
 Metanephric adenoma 
Malignant neoplasms 
 Clear cell carcinoma 
 Papillary renal cell carcinoma 
 Chromophobe renal cell carcinoma 
 Collecting duct carcinoma 
 Renal cell carcinoma, unclassified 
 
Table 5. Genetic classification of renal cell carcinoma (Pantuck et al. 2001). 
 
Tumor type 
  
Tissue origin Genetic alteration 
Clear cell Proximal tubule 3p (VHL tumor suppressor) 
Papillary Proximal tubule +7q (c-Met oncogene),+17,-Y 
Chromophobe Collecting duct -1, -2, -6, -10 
Collecting duct Medullary collecting duct -11 
Oncocytoma Distal tubule -1, -Y, 11q 
Papillary adenoma Proximal tubule +7, +17, -Y 
 
present, indicates poor prognosis. RCC can also be classified based on genetic 
information alone (Table 5) (Pantuck et al. 2001). Familial adult renal neoplasias 
constitute a distinguishable entity among all renal neoplasias (Table 6) (Takahashi 
et al. 2002). The Fuhrman system is used for histological grading (Table 7) 
(Fuhrman et al. 1982), and the TNM classification proposed by UICC in 1997 is 
the staging system most commonly used (Table 8) (Sobin et al. 1997). 
 
Pathophysiology 
Although the etiology of RCC remains elusive, a number of studies have 
investigated potential environmental and genetic risk factors. Cigarette smoking, 
obesity, hypertension, and acquired polycystic kidney disease have been 
consistently associated with RCC. Von Hippel-Lindau (VHL) disease is probably 
the best characterized of the hereditary syndromes, with 23 to 45% of afflicted 
patients developing RCC in their lifetime. The protein product of the VHL gene is 
thought to regulate the transcription of RNA polymerase II and regulate vascular 
endothelial growth factor expression at the posttranscriptional level. Treatment for 
these patients is difficult because several hundred carcinomas may be present in a 
given VHL kidney. Tuberous sclerosis is associated with hamartomas in various  
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Table 6. Familial adult renal neoplasias (Takahashi et al. 2002; Tomlinson et al. 2002). 
 
Disease 
 
Molecular genetics  Clinical features  
 Gene location / 
translocation 
Gene Main lesions Other associated 
lesions 
Von Hippel-Lindau 
disease (VHL) 
3p25 VHL Retinal 
hemangioma, 
CCRCC, cerebellar 
haemangioblastoma, 
pheochromocytoma 
Endocrine 
pancreatic tumors, 
epididymal 
cystadenoma 
Familial non-VHL 
CCRCC with 
chromosome 3 
translocation 
3p14 
3q13.3 
3q21 
FHIT, TRC8? 
Unknown 
Unknown 
 
CCRCC Thyroid, bladder, 
pancreatic, and 
gastric cancer 
Familial non-VHL 
CCRCC without 
chromosome 3 
translocation 
Unknown TRC8? CCRCC  
Hereditary papillary 
cancer (HPRC) 
7q34 c-Met PRCC (type 1) Breast, pancreatic, 
biliary tract, and 
lung cancer, 
malignant melanoma 
Hyperparathyroidism-
jaw tumor  
1q21-q32 Unknown Parathyroid 
adenoma/carcinoma, 
ossifying jaw tumors 
Renal cysts, renal 
hamartoma, adult 
Wilms tumors, 
PRCC (type 1) 
Tuberous sclerosis 
complex 
9q34 
16p13.3 
TSC1 
TSC2 
Renal 
angiomyolipoma, 
rhabdomyoma 
CCRCC 
Birt-Hogg-Dube 
syndrome 
17p12-q11.2 Unknown Multiple 
fibrofolliculoma, 
trichodiscoma, renal 
oncocytoma, 
chromophobe RCC 
PRCC (type 1), 
CCRCC, multiple 
lipoma, pulmonary 
cysts 
Hereditary 
leiomyomatosis and 
renal cell cancer 
1q42-q44 Fumarate hydrase 
(FH) 
Uterine leiomyoma, 
PRCC (type 2) 
Uterine 
leiomyosarcoma, 
skin leiomyoma, 
breast cancer, 
bladder cancer 
Familial papillary 
thyroid carcinoma-
papillary renal 
neoplasia 
1q21 Unknown Papillary thyroid 
carcinoma 
PRCC (type 1), 
papillary renal 
adenoma, renal 
oncocytoma 
Familial oncocytoma Unknown Unknown Renal oncocytoma, 
renal cyst 
 
Hereditary non-
polypotic colorectal 
cancer (HNPCC) 
2p22-p21 
3p22-p21 
2q31-q33 
7p22 
2p16 
hMSH2 
hMLH1 
hPMS1 
hPMS2 
hMSH6 
Colorectal cancer, 
endometrial cancer 
Gastric, ovarian, 
hepatobiliary, renal 
pelvic, ureteral, and 
small intestine 
cancer 
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Table 7. Fuhrman grading system for renal cell carcinoma (Fuhrman et al. 1982). 
 
Grade 1 Round uniform nuclei 
Grade 2 Larger, irregular nuclei and visible nuclei under high power (x400) 
Grade 3 Larger, irregular nuclei and large nucleoli under low power (x200) 
Grade 4 Bizarre, often multilobed nuclei and chromatin clumps 
 
organs, and although more commonly associated with renal angiomyolipomas, 
shows an increased risk for RCC as well. The tuberous sclerosis genes TSC1 and 
TSC2 are tumor-suppressor genes that affect cellular proliferation indirectly. Other 
hereditary RCC-causing syndromes, such as hereditary papillary renal carcinoma, 
familial renal oncocytoma, and the Birt-Hogg-Dube syndrome, have also been 
described and their genetic loci identified (Moyad 2001; Godley and Kim 2002; 
Takahashi et al. 2002). 
 
Markers associated with renal malignancies 
Currently, no clinically useful diagnostic or prognostic marker for RCC 
exists. Clinical diagnosis of RCC is usually confirmed by imaging studies, 
although benign renal lesions sometimes pose a diagnostic challenge. None of the 
serum diagnostic markers studied has reached clinical practice (Zhou and Rubin 
2001). 
Prognostic factors measure tumor aggressiveness and host response both 
natural and therapy-induced. Any factor involved in tumor proliferation, invasion, 
or metastasis, as well as the patient’s specific and nonspecific response to the 
tumor, can contribute to prognosis. Among numerous factors studied for their 
prognostic potential (Table 9), several molecules are promising, but none has 
reached clinical practice (Zhou and Rubin 2001). The role of gelsolin in RCC 
remains to be studied. 
 
Future prospects 
 
Major technical advances are expected to occur during the next few years 
that will transform the TMA technique from an institution-limited screening tool to 
a medium that will enable multi-institutional collaborative studies. Possibly all the 
data produced will also be available to the scientific community more widely 
through the internet, resembling the current practice in the Human Genome Project 
and in some expression-array centers, where freely available genomic sequence 
databases have considerably accelerated the rate at which discoveries are made 
(Manley et al. 2001).  Technical improvements most likely to occur in the near 
future include automated arraying and staining methods, as well as an automated 
image-capturing system allowing remote analysis of the samples in silico (Bova et  
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Table 8. TNM staging system for renal cell carcinoma (Sobin et al. 1997). 
 
Primary Tumor (T) 
 
TX Primary tumor cannot be assessed 
T0 No evidence of primary tumor 
T1 Tumor 7 cm or less in greatest dimension limited to the kidney 
T2 Tumor more than 7 cm in greatest dimension limited to the kidney 
T3 Tumor extends into major veins or invades adrenal gland or perinephric tissues 
but not beyond Gerota’s fascia 
    T3a Tumor invades adrenal gland or perinephric tissues but not beyond Gerota’s 
fascia 
    T3b Tumor grossly extends into renal vein(s) or vena cava below diaphragm 
    T3c Tumor grossly extends into vena cava above diaphragm 
T4 Tumor invades beyond Gerota’s fascia 
 
Regional Lymph Nodes (N) 
 
NX Regional lymph nodes cannot be assessed 
N0 No regional lymph node metastasis 
N1 Metastasis in a single regional lymph node 
N2 
 
Metastasis in more than one regional lymph node 
Distant Metastasis (M) 
 
MX Distant metastasis cannot be assessed 
M0 No distant metastasis 
M1 Distant metastasis 
 
al. 2001; Camp et al. 2002). These developments will further accelerate the 
discovery process, simultaneously placing new demands on database construction 
and maintenance, since this novel way to do TMA research will be more dynamic 
than the traditional method with data laboriously generated by one or very few 
researchers at a time (Manley et al. 2001). 
The challenge that researchers currently encounter – and are likely to 
encounter more often in the future – is how to extract essential information from 
the enormous amount of data being produced by TMAs. Despite developments in 
several aspects of the TMA technique, statistical methods applicable to TMAs have 
not yet undergone detailed study (Manley et al. 2001). The majority of the methods 
will be similar to epidemiological studies in which a large amount of data is 
analyzed. There are, however, features inherent to the TMA technique that must be 
addressed specifically. First, if the results are to be generally utilized in the 
scientific community, data-recording methods must be standardized. Second,  
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Table 9. Potential molecular prognostic markers for renal cell carcinoma. 
 
Marker 
 
Suggested effect 
Acute phase reactants  
 C-reactive protein Predicts prognosis (Ljungberg et al. 1995) 
 Haptoglobin Predicts prognosis (Ljungberg et al. 1995) 
 Ferritin Predicts prognosis (Ljungberg et al. 1995) 
 Uromucoid Predicts prognosis (Ljungberg et al. 1995) 
 Alpha1-antitrypsin Predicts prognosis (Ljungberg et al. 1995) 
Angiogenesis  
 VEGF Serum level correlates with tumor volume (Sato 
et al. 1999) 
 BFGF Serum level increased in disseminated RCC 
(Dosquet et al. 1997) 
 HGF/scatter factor Serum level increased in RCC (Dosquet et al. 
1997) 
Cell adhesion molecules and proteases  
 Urokinase plasminogen activator Predicts early relapse (Hofmann et al. 1996) 
 Plasminogen activator inhibitor Predicts prognosis (Hofmann et al. 1996) 
 CD44 Correlates with progression or recurrence 
(Gilcrease et al. 1999) 
 Alpha-catenin Predicts prognosis (Shimazui et al. 1997) 
 Metallothionein Correlates with invasive growth pattern (Zhang 
and Takenaka 1998) 
 Nm-23 Predicts prognosis (Nakagawa et al. 1998) 
Cell cycle molecules  
 cyclin A Predicts prognosis (Aaltomaa et al. 1999) 
Glycolytic and other enzymes  
 Aldolase A, gamma-enolase Simultaneous elevated expression predicts 
prognosis (Takashi et al. 1993) 
 Calpain 1 Correlates with advanced grade (Braun et al. 
1999) 
 Glutathione S transferase Predicts prognosis (Grignon et al. 1994) 
Cytokines  
 IL-10 Serum level predicts prognosis (Wittke et al. 
1999) 
Growth factors  
 Erythropoietin Serum level predicts prognosis (Ljungberg et al. 
1992) 
 EGF-receptor Predicts prognosis (Moch et al. 1997) 
Proliferation markers  
 Ki-67 Predicts prognosis (Rioux-Leclercq et al. 2000) 
 PCNA Predicts progression (Fischer et al. 1999) 
 TPS Predicts progression (Hobarth et al. 1996) 
Tumor suppressor/oncogenes  
 p53 Predicts progression (Rioux-Leclercq et al. 2000) 
Genetic markers  
 LOH of 9p Predicts progression (Moch et al. 1996) 
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incorporation of TMA data with data from other sources, e.g., from cDNA 
microarrays and cell biology studies, is a constantly evolving field not yet 
thoroughly explored. 
The need to overcome the adverse effect of paraffin-embedding on the 
integrity of RNA, of lipids and of some proteins, has led to a modification of TMA, 
cryoarray (Fejzo and Slamon 2001; Hoos and Cordon-Cardo 2001). The cryoarray 
technique uses frozen tissue as target of molecular analyses. Undoubtedly more 
accurate in some analyses, especially RNA analyses, this novel TMA application 
has the disadvantage that collection of the fresh-frozen tissues required for array 
construction is often slower and more difficult than is use of archived paraffin-
embedded samples. 
Application of the TMA technique to non-neoplastic tissues is a frontier yet 
to be explored. Although several arrays from different institutions, including ours, 
contain non-neoplastic components (Hoos et al. 2001; Rubin et al. 2001), those 
tissues serve as a source of additional information assisting in the interpretation of 
molecular events in malignancy. Expansion of the TMA technique to solely non-
neoplastic cerebral tissues has recently occurred (Goldstine et al. 2002), but the 
applicability of TMAs in study of benign tissues and diseases remains to be fully 
determined by studies including several different target histologies. 
Potential applications of TMA are many: longitudinal arrays with samples 
collected at different time-points from selected patients, lymph node or metastasis 
arrays enabling studies of events leading to invasion and metastasis, cascade-based 
approaches with a selected signalosome comprehensively studied, replicate arrays 
multiplying the number of molecules that can be analyzed from each individual 
tumor. Most likely, combination of data from several sources (TMAs, cDNA 
microarrays, cell arrays) will become more common, assisting efforts to develop a 
comprehensive view of cellular events leading to cancer. The recent observation 
that genomic aberrations at different sites of the disease-causing pathway in 
polycystic lipomembranous osteodysplasia with sclerosing leukoencephalopathy 
(PLOSL) can lead to an identical disease phenotype encourages efforts also to 
profile cancer tumors in order to reveal novel molecular pathways (Paloneva et al. 
2002). Furthermore, the discovery of a specific treatment for metastatic 
gastrointestinal tumors involving a tyrosine kinase inhibitor shows that there exist 
underlying pathologies in cancer that can be discovered and exploited to develop 
novel treatments (Joensuu et al. 2001). Compared to cDNA microarray data, 
sensitive to technique-related variation such as temperature variation during sample 
collection, the replicability of TMA findings is good, an advantage in assessing 
their reliability (Dash et al. 2002). 
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Today’s medicine is revealing the pathoetiology of disease and discovering 
novel specific treatments at a constantly increasing rate. TMAs may in future serve 
as a tool accelerating drug-target discovery and also as a tool to evaluate the effects 
of new drugs on target tissues (Bubendorf 2001; Katsuma and Tsujimoto 2001; 
Anzick and Trent 2002). 
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AIMS OF THE STUDY 
 
Molecular tumor profiling has the potential to extend our knowledge of 
carcinogenic processes by comprehensively portraying molecular events within 
individual tumors. The novel tissue microarray technique may serve as a high-
throughput tool to accelerate these profiling efforts; the TMA technique may also 
serve to validate biomarkers potentially useful in the detection, prognostication, or 
follow-up of malignant tumors. 
 
The aims of this study were: 
 
1) To apply the tissue microarray technique in molecular profiling of urinary 
tract malignancies (I-IV). 
 
2) To study the expression of actin-associated biomarkers gelsolin and E-
cadherin in urothelial carcinoma (I). 
 
3) To study the amplification of chromosomal region 8q24 in bladder cancer 
(II). 
 
4) To profile renal tumors based on Ki-67, on gelsolin, and on PTEN protein 
expression (III). 
 
5) To define the prognostic significance of Ki-67 and gelsolin expression in 
renal clear-cell carcinoma, the most common renal tumor type (IV). 
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MATERIALS AND METHODS 
 
Patient samples 
 
Urothelial cancer 
The urothelial cancer TMA includes archival bladder carcinoma tissue 
samples from 202 cases (146 patients) dated between 1985 and 1995. The material 
came from the Department of Pathology and Laboratory Medicine at the University 
of California, Los Angeles (UCLA) Medical Center, following approval by the 
UCLA Institutional Review Board. Table 10 shows the clinicopathologic data for 
the 146 patients included in the final analysis. For patients with multiple cases, data 
from either the patient's first procedure of any type or their cystectomy case, if 
performed within one month of the first procedure, were used for all subsequent 
analyses. The patients ranged in age from 33 to 94 years, with a mean age of 67 
years. The male-to-female ratio was 3.6:1. There were 57 Tis/Ta/T1 noninvasive or 
superficially (lamina propria) invasive tumors, and the remaining 89 were deeply 
invasive, including 44 T2, 35 T3, and 10 T4 tumors. There were 8 CIS, 6 grade 1, 
40 grade 2, and 92 grade 3 tumors. Detailed demographic, pathologic, and clinical 
information including treatment and follow-up data for at least 5 years was 
incorporated into a correlative database linked to the tissue specimens. In addition, 
data from the original pathology reports were utilized for analysis. Tumor registry 
data including treatment, recurrence, and survival data came from the UCLA 
Cancer Program of the Jonsson Comprehensive Cancer Center. 
 
Renal cancer 
For the renal cancer TMA, a total of 355 formalin-fixed paraffin-embedded 
primary renal carcinoma specimens came from the Department of Pathology and 
Laboratory Medicine at the University of California, Los Angeles (UCLA) Medical 
Center, from patients undergoing surgery for RCC between the years 1987 and 
1999, following approval by the UCLA Institutional Review Board. A total of 257 
representative clear-cell carcinoma specimens were chosen for detailed analyses; 
215 of these were radical nephrectomy and 42 partial nephrectomy specimens. 
Table 11A illustrates the distribution of the specimens representing clear-cell 
morphology according to stage and grade. The clinical characteristics of this study 
population are illustrated in Table 11B. For the other renal tumor subtypes, the 
specimens were analyzed solely according to tumor morphology, excluding grade 
and stage from the analyses. Survival data for the clear-cell RCC tumors were 
obtained by reviewing the hospital records after approval by the UCLA 
Institutional Review Board. Outcome assessment was based on chart review of  
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Table 10. Characteristics of 146 bladder cancer patients by age, gender, tumor grade, stage, 
and surgical procedure. 
 
Characteristics 
 
Number of patients (%) 
Gender  
male 114 (77.7) 
female 32 (22.3) 
Age, years (mean) 67 (range 33-94)  
Grade  
1 6 (4.1) 
2 40 (27.4) 
3 92 (63.0) 
CIS 8 (5.5) 
Stage  
Tis 8 (5.5) 
Ta, T1 49 (33.6) 
T2 44 (30.1) 
T3 35 (24.0) 
T4 10 (6.8) 
Procedure  
Transurethral resection 58 (39.7) 
Cystectomy 88 (60.3) 
 
Table 11. Characteristics of clear-cell RCC study population. 
A) Tumor grade and stage distribution. 
 Grade 1 Grade 2 Grade 3 Grade 4 Total 
Stage 1 10 59 17 0 86 
Stage 2 2 36 11 2 51 
Stage 3 0 43 35 8 86 
Stage 4 0 3 4 2 9 
Total 12 141 67 12 232* 
*Stage information missing for 25 of 257 tumors. 
B) Clinical data for the 257 clear-cell RCC patients. 
Gender, male/female 167/90 
Age, years (mean) 68 (range 33-92) 
Follow-up, months (mean) 34 (range 0-138) 
Alive* 108 
Deceased / RCC 95 
Deceased /other causes 37 
*Follow-up data missing for 17 patients. 
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demographic, clinical, and pathologic data. Patients were evaluated from 
histological diagnosis to the last known follow-up. 
 
 
Tissue microarrays 
 
For the urothelial cancer TMA, the original hematoxylin and eosin (H&E)-
stained case slides were reviewed utilizing the 1997 TNM classification (Sobin et 
al. 1997). During this review, slides containing tumor, adjacent dysplasia, and 
distant benign fields were selected and marked as such by designated colored ink. 
TMA blocks were constructed following the original technique described by 
Kononen and colleagues (Kononen et al. 1998). Where available, four 
representative tissue samples from each selected area were included in the array. 
Analysis was limited to urothelial carcinoma cases, including 140 from the bladder 
(2 of which showed small cell differentiation, one showed signet ring features, and 
one accompanied concomitant renal pelvis urothelial carcinoma), 3 from the renal 
pelvis alone, and 3 from the ureter alone. Metastatic tumors and tumors showing 
exclusive squamous cell carcinoma and adenocarcinoma differentiation were 
excluded from analysis. Final analysis included 146 patients, 202 cases, and 1208 
tissue spots. 
For each case, attempts were made to obtain not only tumor areas, but also 
adjacent dysplastic areas and distant benign fields. These field samples, which 
include progressive changes from benign, to adjacent dysplasia, and finally to CIS, 
provided a mechanism to study how marker expressions are altered in the early 
stage of the malignant process. The benign fields came from the ureter or urethral 
resection margins (for cystectomy specimens) or from benign-appearing 
urothelium at least 5 mm distant from the sampled tumor (for transurethral 
resection). A total of 81 benign field, 8 adjacent dysplasia, and 40 informative CIS 
samples were included. 
For the renal cancer TMA, the original tumors were staged according to 
TNM classification, graded according to Fuhrman, and histologically subtyped 
according to the recommendations of the UICC (Fuhrman et al. 1982; Sobin et al. 
1997). Four core tissue biopsies 0.6 mm in diameter were taken from selected 
morphologically representative regions of each paraffin-embedded renal tumor and 
precisely arrayed by use of a custom-built instrument as previously described 
(Kononen et al. 1998). For each tumor, three of the biopsies were taken from tumor 
areas, and one biopsy from a benign region of the sample. 
Sections 4 µm thick of the resulting tumor TMA blocks were transferred to 
glass slides by the paraffin sectioning aid system (Instrumedics Inc., Hackensack, 
NJ, USA). 
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Immunohistochemistry 
 
H&E-stained array sections were evaluated histopathologically in blinded 
fashion to validate the diagnostic morphology of each array spot. Commercial 
antibody preparations were utilized for the analyses of p53 (Dako Corporation, 
Carpenteria, CA, USA), E-cadherin (Zymed, San Francisco, CA, USA), Ki-67 
(Dako), PTEN (Zymed), and gelsolin (Sigma, St. Louis, MO, USA). 
For IHC staining of gelsolin, a standard two-step indirect avidin-biotin 
complex (ABC) method was used (Vector Laboratories, Burlingame, CA, USA). 
Tissue array sections (4 µm thick) were cut immediately before staining and were 
heated to 56 °C for 20 minutes, followed by deparaffinization in xylene. These 
sections were rehydrated in graded alcohols and endogenous peroxidase quenched 
with 3% hydrogen peroxide in methanol at room temperature. The sections were 
then placed in a 95 °C solution of 0.01 M sodium citrate buffer (pH 6.0) for antigen 
retrieval. Protein blocking was accomplished through application of 5% normal 
horse serum for 30 minutes. Endogenous biotin was blocked with sequential 
application of avidin D, then biotin (A/B blocking system). Primary mouse anti-
gelsolin monoclonal IgG1 antibody was applied at a 1:750 dilution for 60 minutes 
at room temperature. After washing, biotinylated horse antimouse IgG was applied 
for 30 minutes at room temperature. The ABC complex was applied for 25 minutes 
with diaminobenzidine (DAB) used as the chromogen. Phosphate-buffered saline 
(10 mM), pH 7.4, was used for all intermediate wash steps, and a moist humidity 
chamber was used for prolonged incubations. The sections were counterstained 
with Harris hematoxylin, followed by dehydration and mounting. For staining of 
p53, E-cadherin, and Ki-67, the DakoEnvision biotin-free dextran peroxidase 
staining system was used, as was the Dako Autostainer automated staining system, 
and for PTEN, the manual Vector Elite avidin-biotin conjugate kit. 
Tissue samples with known expression for each marker served as positive 
controls (Ki-67 and p53 for high-grade breast carcinoma tissue sections; gelsolin 
and E-cadherin for normal prostate tissue sections). Negative controls were 
sections treated as described above, but with the primary antibody replaced with 
pooled nonimmune mouse IgG of the same concentration, or with the primary 
antibody omitted as a null slide. All sections were analyzed with a BX-40 
brightfield microscope (Olympus, Tokyo, Japan) under x10-20 objectives. When 
questions arose concerning tissue morphology, H&E-stained sections were 
reviewed for confirmation. 
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Fluorescence in situ hybridization 
 
The bacterial artificial chromosome (BAC) clone RP11-184M21 (GenBank 
accession number AC090798) residing in the center of the reported amplified 
region served as a specific probe to detect copy number alterations in the 8q24 
chromosomal region. This probe was random primed with Spectrum Orange. FISH 
was performed for the TMAs following the protocol recently described by 
Andersen and colleagues (Andersen et al. 2001). 
 
Evaluation of protein expression 
 
Quantitative assessment of antibody staining in the bladder cancer TMA 
and renal cancer TMA was performed blinded to clinicopathologic variables. The 
intensity of DAB brown chromogen staining (Max) was graded. For the nuclear-
staining markers p53 and Ki-67, the 0 to 3 scale was: 0, negative; 1, weak staining; 
2, moderate staining; 3, strong staining. For non-nuclear staining of gelsolin and E-
cadherin, the 0 to 4 scale was: 0, negative; 1, weak staining; 2, weak but distinct 
staining; 3, moderate staining; 4, strong staining. Gelsolin and PTEN have a 
cytoplasmic staining pattern, whereas E-cadherin has a membrane staining pattern. 
The proportion of analyzed cells staining positively (Pos) was also recorded. For 
each marker, the Max, Pos, and the product of both (MaxPos), obtained by 
multiplying Max with Pos, were determined. For PTEN, Pos value was the only 
parameter analyzed. The median value of repeated core spots representing each 
area of interest for each sample was used for the final analysis. 
 
Evaluation of genomic amplification 
 
Evaluation of amplification at chromosomal region 8q24 was performed with a 
Leica DMR fluorescence microscope workstation for all patients demonstrating 
specific hybridization in at least one morphologically representative tumor spot. 
High-copy amplification was defined as the presence of at least 10 signals or tight 
clusters of at least 5 signals per cell in at least 5% of tumor cells. The main reasons 
for failed scoring of a spot were unrepresentative spot morphology, weak signal, 
and autofluorescence. 
 
Statistical analyses 
 
For the bladder cancer TMA, the association of marker expression versus 
clinicopathologic parameters was demonstrated in several ways. First, mean 
±standard error of MaxPos was analyzed against progressive field changes, tumor 
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grade, and stage. The Student t-test, analysis of variance (ANOVA), and the 
nonparametric Kruskal-Wallis tests were used to test whether the immunoreactivity 
of each marker differed between groups defined by the clinicopathologic 
parameters grade and stage. To analyze the recurrence risk of multiple 
clinicopathologic and marker expression variables, multivariate logistic regression 
was used. The adjusted odds ratios (relative risks) and their respective p-values 
were determined. Kaplan-Meier curves were used to estimate recurrence-free time 
curves, and the log rank test served to test whether curves differed between groups. 
The Cox proportional hazards model was used to assess which covariates affected 
recurrence-free time. For each covariate, relative hazard rate and associated p-value 
were reported. For all analyses, a p-value less than 0.05 was considered significant, 
and analyses were performed with the software package R (url:http://cran.r-
project.org/). 
For analysis between Ki-67 or p53 expression and 8q24 amplification in the 
bladder cancer TMA, each spot was given a score from 0 to 300 for the biomarker 
analyzed, by multiplying the maximal intensity of staining (scale 0-3) by the 
percentage of positively staining tumor cells (scale 0-100). The median biomarker 
expression score of each tumor was calculated from the available 1 to 4 spots per 
tumor and used in further analyses. The standard deviation of biomarker expression 
was calculated from the mean expression of each biomarker. The Mann-Whitney 
test was performed to compare median biomarker expression between amplified 
and non-amplified tumors, and to compare times of removal between metastases. 
For clear-cell RCC TMA analyses, the association between biomarker 
outcome measures and the various pathological parameters was studied by mean 
and confidence interval plots and the Kruskal-Wallis test. The recursive 
partitioning method (RPART function in S-Plus, Insightful Corporation, Seattle, 
WA, USA) served for survival-tree analysis to find appropriate cutoffs for 
classifying patients by Ki-67 and gelsolin expression. Kaplan-Meier curves were 
used to estimate survival, and the log rank test and the Wilcoxon test to test 
whether curves differed between groups. For the Kaplan-Meier curves, the tumor 
specimens were categorized into two groups (Ki-67-negative and Ki-67-positive) 
according to Ki-67 status, with all tumors presenting no Ki-67 staining considered 
negative, and all others positive. Furthermore, the specimens were also categorized 
into two groups (gelsolin-positive and gelsolin-negative). The gelsolin-positive 
group consisted of tumors with gelsolin staining in every tumor cell, and the 
gelsolin-negative group of all other tumors, thus including tumors with partial or 
non-perceptible gelsolin staining. To assess which covariates predicted survival, 
univariate and multivariate Cox proportional hazards models were used. Covariates 
included Ki-67 and gelsolin expression, grade, stage (pT), gender, and age at 
diagnosis. The proportional hazards assumption was confirmed by Schoenfeld 
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residuals. The relative hazard rate and the associated p-values were determined for 
each covariate. For all analyses, a p-value of less than 0.05 was accepted as 
significant, and the analyses were carried out with the software package SAS. After 
fitting a multivariate regression model, the default SAS stepwise procedure was 
used to eliminate insignificant covariates from the model. Patients with other 
covariates or biomarker outcome measures missing were eliminated from analysis. 
Cancer-specific survival was defined as time from nephrectomy to last follow-up 
contact (alive/dead), taking cause of death into account (died of RCC/ died of other 
causes). The Pearson Chi-square test was used to assess the relationship between 
dichotomized staining phenotypes of the tumors for Ki-67 and gelsolin. To 
compare the median expression of the biomarkers gelsolin, Ki-67, and PTEN 
between the renal tumor subtypes, the median biomarker expression value 
constructed from the expression values of the three cancer tissue spots for each 
tumor was used in analyses. For sarcomatoid tumors, only the tissue spots with 
sarcomatoid morphology were included in analyses. The Wilcoxon two-sample test 
was performed to analyze biomarker expression between tumor types. 
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RESULTS AND DISCUSSION 
 
Biomarker expression in bladder cancer (I-II) 
 
Understanding the oncogenic processes leading to recurrence and 
progression in urothelial carcinoma would potentially lead to more accurate 
prognostication and to development of novel specific treatments for this 
malignancy. Although much progress has been made in recent years in identifying 
molecular events that lead to development of cancer, the exact mechanisms 
underlying the evolution of malignant progressive phenotypes remain poorly 
understood. For instance, the exact biochemical events leading to cancer invasion 
or recurrence have yet to be determined. Understanding these mechanisms may 
have an impact on the development of markers that can be used to define an 
individual's risk for tumor progression and to customize appropriate management 
strategies. 
Changes in cellular motility occur frequently in malignancies with invasive 
potential, such as bladder cancer. In general, it has been assumed that alterations in 
the cytoskeletal protein actin, a major factor in the structure and motility of the cell, 
play an important role in cell invasion and metastasis, even though the exact 
mechanisms remain to be fully elucidated. The actin network is a complex 
structural and functional system of all eukaryotic cells (Pollard and Cooper 1986). 
Molecular mechanisms underlying actin remodeling involve several oncogenic 
signal transduction pathways, the most notable being the small GTPase of the Ras 
superfamily of proteins: Rac, Rho, and Cdc42 (Nobes and Hall 1995; Olson et al. 
1995). In addition, the actin polymerization process is regulated by numerous 
actin-binding and actin-regulatory proteins (Way and Weeds 1990; Singer 1992). 
Many of these proteins (gelsolin, E-cadherin, vinculin) have tumor-suppressor 
functions individually (Vleminckx et al. 1991; Rodriguez Fernandez et al. 1992; 
Prasad et al. 1993; Tanaka et al. 1995). A comprehensive and simultaneous 
analysis of all actin-related molecules, rather than one isolated molecule at a time, 
will therefore be necessary for a clearer understanding of how actin is associated 
with malignant phenotypic changes. One genomic region involved in the 
development of a relatively large fraction of urothelial cancers is 8q24 (Sauter et al. 
1995; Fadl-Elmula et al. 2001). Less is known about the relationship of 8q24 
amplification and the expression of biomarkers p53 and Ki-67, which in urothelial 
cancer are frequently overexpressed (Lipponen 1993; Pfister et al. 1999). 
The TMA technique provides a convenient high-throughput tissue-based 
tool for in situ gene dosage and protein expression studies (Kononen et al. 1998). 
This technique, utilized to rapidly profile a number of molecular markers, produces 
results comparing well with those by standard methods (Bubendorf et al. 1999b; 
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Bärlund et al. 2000; Camp et al. 2000; Gillett et al. 2000). In our study, the two 
most notable actin-binding proteins, gelsolin and E-cadherin, were evaluated as 
markers for urothelial carcinoma recurrence and progression utilizing a bladder 
cancer TMA. Their expression patterns were also compared with clinicopathologic 
characteristics of tumor progression and with the expression patterns of two other 
well-studied markers, Ki-67 and p53. Amplification of chromosomal region 8q24, 
harboring several potentially cancer-related genes, was also studied, and the 
findings were correlated with Ki-67 and p53 expression. 
 
Biomarker analyses 
 Ki-67 and p53 showed an exclusively nuclear staining pattern, gelsolin 
showed a cytoplasmic staining pattern, and E-cadherin a membrane staining 
pattern. Gelsolin stained not only the urothelium, but also stromal tissue, including 
some smooth muscle cells and endothelium. For each marker, the maximum 
intensity of staining (Max), the proportion of analyzed cells staining (Pos), and the 
product of both (MaxPos), obtained by multiplying Max by Pos, were determined. 
Both Ki-67 and p53 showed a similarly progressive increased MaxPos from 
benign, to adjacent dysplasia, to CIS, and from low-grade to high-grade tumors. 
Gelsolin MaxPos decreased in the dysplastic and CIS field lesions compared with 
levels in benign urothelium (p<0.05 by ANOVA). Although still lower in tumor 
samples than in the benign urothelium, gelsolin MaxPos increased with increase in 
tumor grade (p<0.05 by ANOVA). E-cadherin MaxPos was also lower in the 
adjacent dysplastic and CIS lesions compared with levels in benign urothelium, and 
there occurred a gradual decrease in MaxPos with increase in tumor grade, contrary 
to the trend seen with gelsolin. This decrease was also statistically significant 
(p<0.05 by ANOVA). It is noteworthy that E-cadherin expression, but not gelsolin 
expression, was lower in CIS lesions than in grade 1 lesions (p<0.05 by Student t-
test). This is consistent with the fact that CIS is a high-grade noninvasive lesion, 
supported by higher Ki-67 and p53 MaxPos in CIS than in low-grade tumors. 
 Table 12 compares the MaxPos of each marker in different tumor stages, 
from noninvasive (Ta/Tis) to superficially invasive (limited to the lamina propria, 
T1) to deeply invasive (invasion to or beyond the muscularis propria, T2 and 
above). One hundred cases had informative data across all markers. Both gelsolin 
and p53 showed a significantly increased MaxPos, with progression of tumor 
invasion (p<0.05 by ANOVA). E-cadherin showed a marginal association (p<0.1 
by ANOVA), and Ki-67 showed no significant association with tumor stage. 
Correlation matrix analysis for the interrelationship of these markers using the 
MaxPos value showed that, except for some associations between Ki-67 and p53 
(r=0.28), all other marker matrices had an r-value less than 0.20, indicating that 
these markers were expressed rather independently in individual patient samples. 
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Table 12. Comparison of marker expression (MaxPos, mean±SE) among noninvasive 
(Ta/Tis), superficially invasive (T1), and deeply invasive (T2-T4) urothelial tumors (p-
values calculated by ANOVA) (n=130). 
 
Biomarkers Ta/Tis (n=33) T1 (n=18) T2-T4 (n=79) 
 
p-value 
Gelsolin 90.0±9.5 126.5±12.0 153.0±13.9 < 0.05 
E-cadherin 138.7±13.8 161.0±14.6 120±10.8 > 0.05 
p53 32.1±4.6 38.6±4.3 68.8±8.5 < 0.05 
Ki-67 35.7±5.7 40±5.2 31.5±8.0 > 0.05 
ANOVA = analysis of variance. MaxPos = maximum staining intensity multiplied by 
percentage of positively staining cells. 
 
Gelsolin is associated with the regulation of actin cytoskeleton dynamics. It 
severs assembled actin filaments and caps the fast-growing plus-end of a free or 
newly severed filament (Kwiatkowski 1999). It is a prominent substrate of caspase-
3 activity in vitro and is therefore an important effector of cellular apoptosis 
(Kothakota et al. 1997). Gelsolin expression is down-regulated in 60 to 90% of 
breast, bladder, prostate, and lung carcinomas (Asch et al. 1996; Tanaka et al. 
1995; Lee et al. 1999; Shieh et al. 1999). Tanaka and colleagues demonstrated in 
the majority of mice tested that the addition of retroviral gelsolin cDNA constructs 
results in marked and reproducible tumor growth inhibition and prolonged survival 
time (Tanaka et al. 1999). These findings demonstrate the tumor-suppressor effect 
of the gelsolin gene and its potential for treatment of human urinary bladder 
carcinomas. No in vivo study of gelsolin expression in actual human bladder 
carcinoma samples exists, however. Our study on urothelial carcinoma TMA 
revealed a distinctive biphasic gelsolin expression pattern in urothelial carcinoma. 
Compared with the normal field, expression decreased in both premalignant and 
malignant lesions, as would be expected from in vitro observations. This decreased 
expression is more striking in the noninvasive lesions, including dysplasia, low-
grade tumor, and even CIS. There did, however, occur a trend toward increased 
expression from noninvasive (Ta/T0) to superficially invasive (T1) and to deeply 
invasive (T2 and above) tumor. A higher gelsolin labeling index (Max or MaxPos) 
was an independent marker for tumor recurrence and progression, particularly for 
high-grade tumors. Acquiring a certain level of gelsolin expression might therefore 
facilitate the conversion of a noninvasive tumor to an invasive one. This is 
consistent with the fact that cytoskeletal proteins play an important role in tumor 
cell motility and invasion. 
A similar gelsolin expression pattern has appeared in other carcinoma types 
such as non-small-cell lung carcinoma and breast carcinoma (Shieh et al. 1999; 
Thor et al. 2001). Thor and colleagues showed that by univariate and multivariate 
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analyses overexpression of gelsolin, epidermal growth factor receptor (EGFR), and 
c-erbB2 significantly predicted poor clinical outcome (Thor et al. 2001). In lymph 
node-positive patients, coexpression of all three markers was associated with 
median disease-specific survival of 3 years (compared with c-erbB2-positive, 
EGFR-positive, and gelsolin-negative patients with their median survival of 6 
years). The biphasic expression pattern of gelsolin is intriguing. First, it suggests 
that epigenetic mechanisms may be involved in the regulation of gelsolin gene 
expression. Second, the increasing expression from noninvasive to invasive tumors 
supports the hypothesis that tumor invasion is attributable to cytoskeletal actin-
associated motility machinery. Third, in view of our positive association between 
increased gelsolin expression and tumor progression, caution is needed when 
developing therapeutic interventions based on gelsolin regulatory strategies. 
Our study confirmed observations from a number of recent studies that 
decreased expression of E-cadherin occurs in urothelial carcinoma, primarily in the 
high-grade tumors (Nakopoulou et al. 2000; Popov et al. 2000; Bornman et al. 
2001; Shariat et al. 2001). Our study also showed, however, that decreased 
expression of E-cadherin is associated with tumor recurrence in low- to 
intermediate-grade tumors. Bornman and colleagues showed that one of the 
potential mechanisms for decreased expression of E-cadherin in urothelial 
carcinoma is related to DNA methylation (Bornman et al. 2001). Altered 
methylation is evident in the nontumor areas of older patients. In their study, 
however, altered methylation of E-cadherin did not perfectly correlate with 
decreased expression in the nontumor areas. This finding suggests that in bladder 
carcinoma, DNA methylation may not be specific for down-regulation of E-
cadherin. In many previous studies, abnormal E-cadherin expression was defined 
arbitrarily by the complete absence of immunoreactivity or by the heterogeneous 
staining of tumor areas. Although our study used semiquantitative Max and 
MaxPos values, overall findings were similar. 
 The association between marker expression and tumor recurrence was 
analyzed by both univariate and multivariate approaches. Table 13 shows the 
results of univariate analysis, in which the mean of staining parameters (Max, Pos, 
and MaxPos) of each marker was compared for patients with tumor recurrence 
versus those without recurrence, after stratification by tumor grade (grade 1-2 vs. 
grade 3). Information on tumor/no tumor recurrence was analyzed for 113 patients, 
38 of whom had grade 1 to 2 tumors, and 75 of whom had grade 3. Patients with 
grade 1 and grade 2 tumors who experienced subsequent tumor recurrence had 
significantly higher Ki-67 MaxPos and p53 Max, as well as lower E-cadherin 
MaxPos, than did patients with no tumor recurrence (p<0.05 for all). For patients 
with grade 3 tumors, however, the gelsolin Max value was significantly higher in 
those with tumor recurrence than in those with none (p<0.05). 
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Table 13. Marker expression vs. recurrence status in urothelial tumors stratified by tumor 
grade (grade 1-2 vs. grade 3)(n = number of tumors). 
 
Recurrence 
status 
 Ki-67 p53 Gelsolin E-cadherin 
 n Max Pos MP Max Pos MP Max Pos MP Max Pos MP 
Grade 1-2              
No recurrence 12 1.2 12 20 0.4 17 31 1.6 56 124 2.3 81 192 
Recurrence 26 1.6 17 37 1.0 21 39 1.7 71 137 1.8 66 124 
Grade 3              
No recurrence 39 1.3 16 29 1.2 30 59 1.4 65 135 1.7 65 139 
Recurrence 36 1.3 18 31 1.4 27 66 2.1 72 162 1.6 61 116 
Max = maximum staining intensity; Pos = percentage of positively staining cells; 
MaxPos=MP=Max multiplied by Pos. p-value determined by Student t-test. Bold numbers 
indicate p < 0.05. 
 
 In multivariate analysis for those with complete follow-up and informative 
data across all markers (n=68), initially in each marker analyzed, including p53 and 
Ki-67, Max outperformed Pos or MaxPos in predicting tumor recurrence. In 
multivariate analysis (Table 14), the significant predictors for probability of tumor 
recurrence were low tumor grade (grade 1-2 of 3) and higher gelsolin and p53 
Max. Tumor stage and expression of Ki-67 and E-cadherin were not significantly 
associated with probability of tumor recurrence. Association of tumor recurrence 
with low tumor grade is not surprising, because low-grade tumors tend to recur. In 
addition, patients with low-grade tumors are less likely to be treated with definitive 
therapy (cystectomy) than are patients with high-grade tumors. In our study, 12% 
of patients with low-grade tumors received a cystectomy, compared with 88% of 
patients with high-grade tumors (p<0.001 by chi-square test). 
 In Cox regression analysis of correlation of marker expression with tumor 
recurrence-free time, all tumor markers reached statistical significance (Table 15). 
Again, similar findings were seen with the Pos or MaxPos value. For tumor 
markers, the strongest association was increased Ki-67, followed by increased 
gelsolin, increased p53, and decreased E-cadherin expression, in decreasing order 
of significance. Patient's age and tumor grade were negatively associated with early 
tumor recurrence. 
 Because negative association between tumor grade and tumor recurrence-
free time may be related to treatment method, Cox regression analysis was 
performed separately in cases stratified for low or intermediate grade (grade 1-2) 
versus high grade (grade 3) and for noninvasive tumors or those superficially 
invasive (Tis/T0/T1) versus deeply invasive (T2-T4). For low- to intermediate-
grade tumors (grade 1-2), both E-cadherin and p53 were significant markers in 
addition to patient age and tumor stage. However, for the high-grade tumors,  
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Table 14. Multivariate analysis for urothelial tumors: significant factors associated with 
recurrence status by logistic regression analysis (n=68). 
 
Factors 
 
OR 95% CI p-value 
Stage 1.76 0.88-3.5 0.11 
Grade 0.12 0.03-0.42 0.001 
Ki-67 Max 1.21 0.58-2.51 0.62 
p53 Max 2.66 1.19-5.95 0.017 
Gelsolin Max 2.60 1.22-5.51 0.013 
E-cadherin Max 1.04 0.55-1.95 0.914 
OR = odds ratio; CI = confidence interval; Max = maximum staining intensity. 
Bold numbers indicate significant factors. 
 
increased gelsolin was the strongest indicator for early tumor recurrence 
(p=0.0025, Table 15), followed by Ki-67 (p=0.031). When superficial (Ta/T0/T1) 
and deeply invasive (T2-T4) tumors were analyzed separately, Ki-67 was the only 
marker significant for the former, with gelsolin the only marker significant for the 
latter. 
 A Kaplan-Meier curve of tumor recurrence time versus staining intensity of 
gelsolin in high-grade tumors showed no tumor recurrence in tumors with negative 
gelsolin staining. The median recurrence time for weak (1+) Max staining was 10 
years, for moderate (2+) staining 7 years, for strong (3+) staining 4 years, and for 
strongest (4+) staining less than one year. These data show that increased gelsolin 
staining intensity in tumor areas is the most important predictor of decreased tumor 
recurrence-free time in high-grade tumors. 
 To further test whether abnormal marker expression in the primary tumor 
predicts the behavior of an individual tumor, expression levels (MaxPos value) of 
markers in tumors with and without progression were compared longitudinally. 
Among 146 patients, 21 had more than one tumor specimen collected at intervals 
of at least one month and had an adequate amount of tissue to be analyzed. These 
samples were included in TMA analysis. For these 21 cases, paired tissue samples 
from the first and last visit were analyzed for any relationship between tumor 
progression and marker expression. Tumor progression was defined as increase in 
either grade (grade 1 to grade 3) or stage (stage 1 to 4). Patients with tumor 
progression (n=14) had an average follow-up time of 25 months, and patients 
without (n=7), an average follow-up time of 21 months. Patients with tumor 
progression showed a significantly higher level of expression for gelsolin than did 
patients without tumor progression in the primary tumor samples (p=0.007), 
indicating that for patients with recurrent tumors increased gelsolin in a primary 
tumor sample predicts progressive behavior. Although Ki-67 and p53 expression  
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Table 15. Multivariate analysis of marker expression versus recurrence-free time in 
urothelial tumors (OR and 95% CI) by Cox regression analysis. 
 
Characteristics  Grade 
 
Stage 
 All tumors 
(n=68) 
 
1-2 
(n=29) 
3 
(n=41) 
Ta/T0/T1 
(n=33) 
≥T2 
(n=37) 
Patient age 
 
0.73 (0.66-0.80) 0.64 (0.52-0.78) 0.74 (0.63-0.87) 0.67 (0.55-0.81) 0.75 (0.66-0.86) 
Grade 
 
0.07 (0.02-0.21) - - 0.30 (0.05-1.79) 0.14 (0.02-0.88) 
Stage 
 
2.07 (1.12-3.62) 4.45 (1.42-14.0) 2.58 (1.06-6.31) - - 
Ki-67 
 
2.55 (1.45-4.47) 2.28 (0.69-7.52) 3.10 (1.11-8.67) 3.76 (1.38-10.3) 1.43 (0.57-3.55) 
p53 
 
1.84 (1.26-2.69) 2.08 (1.06-4.11) 1.58 (0.92-2.70) 1.96 (0.92-4.20) 1.38 (0.86-2.21) 
Gelsolin 
 
2.08 (1.31-3.31) 1.09 (0.37-3.21) 3.21 (1.51-6.83) 1.76 (0.73-4.25) 2.17 (1.15-4.12) 
E-cadherin 
 
0.62 (0.43-0.89) 0.45 (0.24-0.85) 1.15 (0.61-2.18) 0.32 (0.29-1.02) 1.00 (0.50-2.00) 
OR = odds ratio; CI = confidence interval. Bold numbers indicate p < 0.05; Max values (maximum 
staining intensity) used. 
 
was increased, and E-cadherin expression was decreased in progressing tumors, 
these differences did not reach statistical significance. No statistically significant 
difference appeared in marker expression between primary and recurrent tumor 
samples. 
Although a wide spectrum of lesions were analyzed, the small sample size 
for some of these lesions (only six grade 1 tumors) precluded comprehensive 
analysis. Although this was a limitation of our study, the analysis provided strong 
support for the use of gelsolin as a potential prognostic marker for high-grade 
urothelial carcinomas. Most bladder tumors (70-80%) are classified as superficial 
(Bane et al. 1996). Between 50 and 70% of patients with superficial tumors will 
develop new superficial TCC, often within 12 months of diagnosis. In 10 to 20% of 
these patients, these tumors will infiltrate the muscular propria (T2-T4) (Heney et 
al. 1982). Because only the progressive tumors will eventually lead to cancer-
related death, it is crucial to identify these patients early so that more aggressive 
treatment methods can be applied. 
Ki-67 and p53 stainings were also studied after conversion to a 
positive/negative schema using the threshold reported in the literature (20% of cells 
staining for either marker) (Cordon-Cardo et al. 1997; Popov et al. 1997). Ki-67 
was positive in 75% of CIS lesions and in 17% of grade 1, 55% of grade 2, and 
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50% of grade 3 tumors; p53 was positive in 38% of CIS lesions and in 17% of 
grade 1, 38% of grade 2, and 53% of grade 3 tumors. These findings are similar to 
those in the literature. When marker expression was analyzed against tumor 
recurrence, however, the Max value of each marker provided stronger associations 
than did Pos or MaxPos values. In our analysis of marker expression versus tumor 
recurrence, the results were similar, regardless of the values (Max, Pos, or MaxPos) 
used. This finding differs slightly from those of other investigators, and emphasizes 
the fact that the results of such studies depend on the quantitative method (Cordon-
Cardo et al. 1997; Popov et al. 1997). 
Findings regarding these four markers demonstrate that expression patterns 
for the cytoskeletal proteins gelsolin and E-cadherin are distinctive from those of 
Ki-67 and p53 in bladder cancer. Gelsolin and E-cadherin show an overall lower 
expression than do corresponding benign fields. However, gelsolin is low mainly in 
premalignant and preinvasive lesions. In tumors, gelsolin expression generally 
increases with increasing grade and stage. Elevated expression of gelsolin relative 
to that in premalignant lesions is a strong indicator for the probability of tumor 
recurrence, early tumor recurrence, and tumor progression, particularly for high-
grade tumors. Conversely, E-cadherin decreases as tumor grade increases. This 
finding provides in vivo evidence to support the theory that distinctive patterns of 
actin family gene expression may occur in different stages of the malignant 
transformation process. Whereas decreased expression of gelsolin occurs at the 
early stages of malignant transformation, increased gelsolin expression may play a 
role in converting the less aggressive superficial tumor to a more aggressive 
invasive tumor. This study shows the value of examining the utility of these 
markers as prognostic indicators for urothelial carcinomas. 
 
8q24 amplification 
We evaluated the frequency of 8q24 amplification in urothelial carcinoma, 
focusing on high-grade tumors and metastases, using primary tumor samples from 
131 patients (Table 16). Of these patients, 42 had low- to intermediate-grade (grade 
1-2) disease, and 89 had high-grade (grade 3) disease. Metastases were available 
from 39 patients. The majority of primary tumors and metastases were represented 
by three cancer tissue spots in the array. High-copy amplification (at least 10 
signals or tight clusters of at least 5 signals/cell in at least 5% of tumor cells) 
occurred in either a primary tumor or a metastasis in 10% (16/159) of the patients. 
Concordance of 8q24 amplification between the spots for each individual tumor 
and metastasis was 100%. Of the primary tumors, amplification was most 
frequently observed in high-grade tumors (10%), with low- to intermediate-grade 
tumors amplified less frequently (7%). None of the grade 1 tumors was amplified. 
Interestingly, one of the patients with bladder TCC had recurrent TCC in the renal  
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Table 16. 8q24 amplification in primary bladder tumors and metastases. 
 
 Patients with 8q24 amplification 
(n amplified / n total (%)) 
 
Grade 1 0/5 (0) 
Grade 2 3/37 (8) 
Grade 3 9/89 (10) 
Primary tumors (total) 12/131 (9) 
  
Lymph node metastasis 0/28 (0) 
Metastasis (other sites) 4/11 (36) 
Metastatic patients (total) 4/39 (10) 
 
pelvis 5 years later. Whereas this bladder TCC showed no amplification at 8q24, 
the renal pelvic TCC did. The small number of tumors harboring the 8q24 
amplification has to be taken into account in assessing the importance of these 
findings. 
These findings support the previous notion that the frequency of 
chromosomal region 8q24 amplification increases with progressing tumor grade, 
being highest in high-grade TCC tumors. The proportions of low to intermediate 
grade (grade 1-2) and high-grade (grade 3) tumors showing amplification (7% and 
10%, correspondingly) in this study are concordant with those in the literature 
(Kallioniemi et al. 1995; Sauter et al. 1995; Richter et al. 1997). Furthermore, the 
finding that 8q24 is not amplified in grade 1 tumors fits well with the hypothesis 
that genomic amplifications are more abundant in tumors of higher grade, yet our 
small sample size has to be taken into account in assessing the significance of this 
observation. 
As metastatic lesions commonly occur in urothelial cancer, we studied the 
frequency of 8q24 amplification in metastatic lesions to discover how it relates to 
the amplification frequency in primary tumors. Amplification was detected in 4 of 
39 (10%) of the patients having metastases (Table 17). None of 30 lymph node 
metastases and 6 of 16 (38%) metastases at other sites demonstrated amplification 
(Table 17). Of the 4 patients whose metastases showed 8q24 amplifications, 2 had 
matching primary tumor tissue available, neither of whom showed amplification in 
their primary tumor, whereas their metastases to the labium and lung (Figure 3) did 
show amplification. In the remaining 2 cases, no primary tumor was available, but 
patient histories indicated that both had grade 3 primary tumors 5 and 6 years 
earlier. The follow-up times between lymph node metastases and other types of 
metastases differed greatly, with 90% of lymph node metastases removed during 
cystectomy or other surgical treatment for the primary tumor, whereas the  
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Table 17. 8q24 amplification status of bladder tumor metastases. 
 
 Amplified metastases 
 
All metastases 
Regional metastases   
    Lymph node 0 28 
   
Distant metastases   
    Lymph node 0 2 
    Vagina 0 4 
    Lung 2 3 
    Labium 2 2 
    Liver 1 2 
    Bowel 0 2 
    Retroperitoneum 1 1 
    Pelvic soft tissue 0 1 
    Calf 0 1 
   
All metastases 6 46 
 
metastases of other sites were usually removed long after treatment for the primary 
tumor. Median times of removal were 0 months for lymph node metastases and 26 
months for metastases at other sites (p<0.0001). The elapsed median time between 
removal of the primary tumor and of the 8q24-amplified distant metastases was 42 
months, longer than the median of 22 months for non-amplified distant metastases, 
a difference not statistically significant (p=0.30). 
The finding of amplification in metastatic lesions but not in the 
corresponding primary lesions of the same patient is intriguing. In our study, 33% 
of distant metastases showed amplification, whereas no regional metastases did. 
Since genetic amplifications are likely to accumulate during the carcinogenic 
process, it is possible that the later the metastases are removed, the more likely they 
possess genomic amplifications of 8q and other genomic regions. The alternative 
explanation is that the area of 8q may harbor genes essential in driving the potential 
for tumors to metastasize to distant sites. Our results showing amplification in a 
defined chromosomal region in a subgroup of bladder tumors and metastases 
parallel the findings of the c-erbB2 proto-oncogene amplification status of breast 
tumors and their corresponding metastases (Gancberg et al. 2002). Furthermore, 
that a molecular signature of metastasis in primary solid tumors has been reported 
for several tumor types shows that a subset of primary tumors may resemble 
metastases with respect to this gene-expression signature (Ramaswamy et al. 
2003). Our own findings imply the existence of molecularly heterogeneous 
subgroups of bladder tumors and metastases defined by 8q24 amplification status. 
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Figure 3. 8q24 amplification of a transitional cell carcinoma lung metastasis, visible as 
multiple hybridization signals (Spectrum Orange) within a tumor cell nucleus (DAPI). 
Original magnification: x100. 
 
 
Since p53 and Ki-67 protein expression correlates with tumor grade, as 
does 8q24 amplification, we studied the possible correlation between 8q24 
amplification and expression of these biomarkers in the same patient group, using 
the same arrays that we analyzed for the 8q24 amplification. In tumors carrying 
8q24 amplification, expression of each biomarker varied widely. Similar wide 
variation in expression was noted also in tumors lacking this amplification (Table 
18). The expression of Ki-67 was, however, significantly higher in tumors 
possessing the amplification than in tumors without it (p<0.005). Expression of p53 
showed a similar trend, but due to wide variation this did not reach statistical 
significance (p=0.19). Although a correlation between amplification at 8q24 and 
expression of Ki-67 was detectable (p<0.005), a causative relationship between 
8q24 amplification and increased Ki-67 expression can obviously not be suggested 
based on this study alone. Since Ki-67 is a marker of active cell proliferation, 
however, this finding parallels the assumption that those urothelial tumors showing 
8q24 amplification are also more proliferative and thus potentially more 
aggressive. The location of the MDM2-binding protein (MTBP) in chromosomal 
region 8q24 and its potential involvement in the p53 apoptotic pathway made the 
p53 expression analysis interesting (Mayo et al. 2002). Although p53 expression 
showed a correlative trend, it did not reach statistical significance (p=0.19). Studies 
with larger sample size may confirm this tentative finding. 
Our results show that in a subgroup of primary bladder tumors and 
metastases, high-copy amplification of the 8q24 chromosomal region occurs. The 
primary tumors and metastases carrying 8q24 amplification frequently 
overexpressed Ki-67. It remains to be seen whether a more detailed analysis of the 
8q24 region in urothelial carcinoma will reveal specific alterations in genes, and 
whether these may be useful for tumor classification or as specific targets of 
treatment. 
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Table 18. Biomarker expression in primary bladder tumors. 
 
 Non-amplified tumors 
(n=119) 
Amplified tumors 
(n=12) 
 
 Median score Range SD Median score Range SD p 
p53 5 0-300 75 25 0-240 98 0.19 
Ki-67 10 0-210 40 55 10-240 63 <0.005 
 
 
Biomarker expression in renal cell carcinoma (III-IV) 
 
RCC subtypes 
Ki-67, gelsolin, and PTEN staining levels were first assessed in the RCC 
subtypes within the TMA. As expected, Ki-67 expression was higher in 
sarcomatoid than in clear-cell (Figure 4, p<0.05) or papillary (p<0.005) tumors. 
Interestingly, gelsolin expression was higher in papillary tumors than in clear-cell 
tumors (p<0.0001) or in sarcomatoid tumors (p<0.05). PTEN expression did not 
significantly differ between sarcomatoid and clear-cell or papillary tumors. 
However, PTEN expression was lower in clear-cell than in papillary tumors 
(p<0.005). Study of the protein expression of Ki-67, gelsolin, and PTEN revealed 
distinct biomarker expression profiles for each of the RCC subtypes. As the 
prognosis of sarcomatoid tumors is worse than that of other renal tumors (Pantuck 
et al. 2001), one might expect that the malignant phenotype would be reflected in 
the tumor’s biomarker expression, as well. Ki-67, a marker of active cell 
proliferation, is indeed highly expressed in sarcomatoid tumors, in concordance 
with the aggressive nature of this tumor type (Delahunt 1999; Moch et al. 2000), 
and confirms the reports of increased Ki-67 expression in sarcomatoid tumors 
(Renshaw et al. 1998; Kanamaru et al. 1999; Kuroiwa et al. 2001). On the other 
hand, gelsolin expression is low in clear-cell and sarcomatoid tumors, but high in 
papillary tumors. This is intriguing in the light of reports of a tumor-suppressive 
role for gelsolin in cancers of the bladder, prostate, and breast (Tanaka et al. 1995; 
Lee et al. 1999; Winston et al. 2001), because our results showing differences in 
gelsolin expression suggest that gelsolin may play multiple roles within renal 
tumor types. The tumor-suppressor protein PTEN was highly expressed in both 
papillary and sarcomatoid tumors, whereas PTEN expression was significantly 
lower in clear-cell than in papillary tumors. In all of these tumor types, however, 
PTEN was generally expressed in 80 to 90% of tumor cells, suggesting that PTEN 
expression is not severely affected in any of these tumor types, and the difference 
between clear-cell and papillary tumors may be a bystander phenomenon. 
Furthermore, we also observed that all but two normal kidney tissue samples in our 
array expressed PTEN in every cell. Further studies controlling for additional  
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Figure 4. Biomarker expression in clear-cell, papillary, and sarcomatoid renal tumors, with 
percentage of positively staining tumor cells on y-axis. Values are mean±SD. 
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variables such as grade, stage, and intensity of staining may fully characterize these 
findings. 
The results thus demonstrate that, compared with clear-cell and papillary 
tumors, sarcomatoid renal tumors have a distinct protein expression profile. Ki-67 
expression in sarcomatoid tumors is significantly higher than in clear-cell or 
papillary tumors, whereas gelsolin expression is lower in sarcomatoid than in 
papillary tumors, and PTEN is highly expressed in all these tumor types. This 
supports the evidence of Ki-67 as a biomarker for renal tumors, whereas the roles 
of gelsolin and PTEN in the carcinogenesis of various renal tumor types remain to 
be elucidated. It must be emphasized that although differences in biomarker 
expression were evident when each tumor subtype was analyzed as a single group, 
differences may exist in expression within these groups when the tumors are 
classified according to clinicopathological parameters such as grade and stage. Our 
detailed analysis of Ki-67 and gelsolin expression in clear-cell RCC already shows 
that comprehensive analysis may reveal additional information concerning the 
stages of the carcinogenic process. 
 
Clear-cell RCC 
Ki-67 and gelsolin expression was further evaluated in the 257 tumors 
representing clear-cell morphology. Ki-67 expression was detected in 175 of 241 
(73%) of the evaluable tumors (mean expression 9% of tumor cells, median 
expression 5%, SD 0.63). Gelsolin expression was detected in 106 of 246 (43%) of 
the evaluable tumors (mean expression 30% of tumor cells, median expression 0%, 
SD 2.67). Ki-67 showed an increase in staining with increasing tumor grade 
(Figure 5, p<0.0001), as did gelsolin (p=0.0037). Although both biomarkers 
showed similar trends of increased staining at higher grades, no correlation 
appeared between gelsolin and Ki-67 expression (ρ=0.087). We also performed 
survival analyses for the clear-cell RCC specimens to clarify the value of Ki-67 
and gelsolin as predictors of survival. When these biomarkers were compared to 
the conventional predictors in univariate and multivariate settings, with cancer-
specific survival as the outcome, multivariate Cox regression analysis for cancer-
specific survival indicated that stage (pT) was a significant prognostic factor 
(p<0.0001), and Ki-67 expression was also a significant prognostic factor 
(p=0.0216), when all covariates were included in the analysis. Higher stage and 
increased Ki-67 expression predicted poor survival. A total of 180 patients were 
included in the multivariate analyses after exclusion of patients with missing 
values. The SAS stepwise procedure indicated that stage was the most important 
predictor (p<0.0001), followed by Ki-67 (p=0.0016). In a multivariate analysis that 
included Ki-67 and grade along with stage, Ki-67 was statistically significant 
(p=0.0309), but grade was not (p=0.1951), suggesting that Ki-67 has predictive  
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Figure 5. Relationship of tumor grade and biomarker expression in clear-cell RCC. Grade 
on x-axis, percentage of positively staining tumor cells on y-axis as mean value +SD. Ki-67 
= black bars. n=13 (grade 1), n=144 (grade 2), n=69 (grade 3), n=15 (grade 4). Gelsolin = 
gray bars. n=11 (grade 1), n=149 (grade 2), n=71 (grade 3), n=15 (grade 4). n=number of 
tumors. 
 
value independent of grade. A correlation between Ki-67 and grade occurred 
(ρ=0.52). It is possible that one of the reasons why grade was nonsignificant is that 
relatively few grade 1 and 4 tumors were included. The analyses used the pT 
staging variable, in which stage is defined for the primary tumor by a pathologist. It 
remains to be seen whether further studies controlling for patients’ nodal and 
metastatic status will reveal novel correlations in subgroups of this population. 
 To evaluate the potential prognostic significance of Ki-67 and gelsolin 
expression in a clinically useful setting, we categorized the patients into groups 
with dichotomized values for the biomarkers to discover prognostic factors. 
Dichotomized Ki-67 and gelsolin expression values were inversely related 
(Pearson Χ2 statistic p=0.0017). Kaplan-Meier plots with cancer-specific survival 
time revealed that patients with Ki-67-negative tumors did better than those with 
Ki-67-positive tumors (Figure 6A, p=0.0006). Gelsolin did not significantly affect 
survival time (Figure 6B, p=0.33) in the same patient group. When the analysis was 
restricted to grade 2 tumors, Ki-67 expression showed no evidence of differing 
survival distributions (p=0.0833), whereas gelsolin expression showed a trend 
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toward differing survival distributions (logrank p=0.0566), in favor of the group 
with positive gelsolin staining. The fact that Ki-67 and gelsolin had been stained in 
the same set of samples made it possible to study whether a combined expression 
profile of these biomarkers would provide additional prognostic information within 
each grade. Patients with Ki-67-positive staining and gelsolin-negative staining 
were compared to patients with Ki-67-negative staining and gelsolin-positive 
staining. Due to the large variation in gelsolin staining in grade 1 and 4 tumors and 
its contribution to noise in the statistical analysis, the sample was stratified to 
include only one grade. In grade 2, analysis with a combined expression profile of 
Ki-67 and gelsolin revealed a difference in cancer-specific survival distributions 
between groups (Figure 6C, log rank statistic p=0.0507), in favor of the group with 
Ki-67-negative/gelsolin-positive tumors. This may suggest that Ki-67 and gelsolin 
are at least partially affected by the same carcinogenic pathways. Other grades 
showed no significant difference in survival. In our study, the regional and distant 
metastatic status of the tumors was never taken into account. However, when 
patients with metastases were excluded from analysis, the same trend was observed 
for grade 2 tumors, but results were not significant, most likely due to small sample 
size (n=55). 
In conclusion, this renal cancer TMA study shows that renal tumor 
profiling utilizing the TMA technique is feasible. Furthermore, these profiles can 
serve as sources of new information on renal carcinogenesis, and, once clinical 
information is incorporated into the analysis, also as validation tools for potential 
prognostic biomarkers. Increased Ki-67 expression predicts poor prognosis both as 
a continuous variable and as a categorized variable at a cutoff value for Ki-67 
staining. For grade 2 tumors, the combined expression profile of the two 
biomarkers may predict survival. As a prognostic biomarker for RCC, Ki-67 shows 
great promise. These findings also suggest an important role for gelsolin in 
carcinogenesis of RCC and should stimulate further cellular study. Future research 
will elucidate the events that cause some of the grade 2 tumors to become more 
aggressive and will assist in development of more effective treatment options for 
advanced disease potentially targeting Ki-67- and gelsolin-related pathways. 
 
Figure 6. Kaplan-Meier curves demonstrating probability of cancer-specific survival for 
clear-cell RCC patients grouped according to biomarker expression. 
A) Ki-67 staining among all grades. a = Ki-67-negative patients (n=62). b = Ki-67-
positive patients (n=167). 
B) Gelsolin staining among all grades. a = gelsolin-negative patients (n=180). b = 
gelsolin-positive patients (n=53). 
C) Combined Ki-67 and gelsolin staining profile in grade 2. a = patients with negative 
Ki-67 staining and positive gelsolin staining (n=15). b = patients with positive   
Ki-67 staining and negative gelsolin staining (n=80). 
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Figure 6A 
 
Figure 6B 
 
Figure 6C 
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Technical aspects of tissue microarrays 
 
 Several issues need to be taken into account during a TMA analysis. 
Selection of the samples to be arrayed is a crucial step; for the future experiments 
to be successful, the review process of the archived samples prior to TMA 
construction has to be done very carefully. Otherwise, if non-representative tissue 
areas are selected, future analyses may be limited, and the results potentially 
misleading. In this respect, RCC TMA is easier to construct than urothelial TMA, 
since renal tumors are often large, with well-defined boundaries, which makes it 
easier to obtain the correct tissue type during TMA construction. In comparison, 
benign uroepithelium and urothelial tumors are often relatively thin 
macroscopically and more difficult to hit with the arrayer. Thus, there likely are 
more empty spots or spots representing non-desired morphology in urothelial TCC 
TMA than in RCC TMA. Cancer type affects the number of cores needed to 
reliably capture the heterogeneity of the tumor; the more heterogeneous the tumor, 
the more cores needed. RCC and TCC are relatively homogeneous tumors 
compared to, for instance, prostate cancer, allowing reliable analyses with a fewer 
cores per tumor. Evaluation of stained slides mainly involves the same issues as 
does the specific staining technique in question, i.e., the issues in IHC TMA 
analysis parallel the issues in IHC analysis on regular tissue slides. 
Recurring malignancies pose another challenge for TMA studies: urothelial 
TCC often recurs, and study of molecular events leading to recurrence or 
progression requires samples from recurrent tumors to enable longitudinal studies 
of biomarker expression, whereas for RCC, tissue collection is often 
straightforward and the course of the disease often shorter, with nephrectomy often 
the primary treatment and repeated operations rare. Analyzing metastases from all 
urinary tract malignancies would potentially benefit the study of processes leading 
to invasion and metastasis, but removing metastases from patients for therapeutic 
or palliative purposes is rarely indicated, and removing metastases strictly for 
research purposes is uncommon. 
A vast amount of data can be rapidly produced in high-throughput fashion 
utilizing the TMA technique. A consecutive analysis of up to 200 molecules in 
hundreds of specimens makes great demands on statistical analyses of TMA data. 
Statistical approaches are being developed to enable an analysis in which both 
molecular and clinical information can be efficiently analyzed on the same basis. 
Our study applied modern statistical methods successfully. In interpreting results, 
accurate clinical information on the patients turned out to be essential. 
Based on our study, the TMA technique benefits the study of urothelial 
carcinoma and RCC as a time- and tissue-preserving, high-throughput screening 
tool. 
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CONCLUDING REMARKS 
 
The tissue microarray technique was developed as an attempt to provide a 
high-throughput tool for studies of cancer tissues. Several studies utilizing the 
TMA technique have investigated malignant tumors for genomic alterations and 
protein expression, providing clues to the pathways associated with malignancy. 
TMA studies focusing on molecular profiling of tumors have, however, thus far 
been rare. 
We studied biomarker expression in cancers of the urinary bladder and 
kidney and showed that bladder tumors had distinct expression profiles for the 
actin-associated proteins gelsolin and E-cadherin, and that increased gelsolin 
expression in high-grade bladder tumors was associated with increased risk for 
progression and recurrence. The traditional biomarkers p53 and Ki-67 also had 
distinct expression profiles in the same samples. Additionally, genomic 
amplification in the chromosomal region 8q24 commonly amplified in bladder 
cancer occurred in a subgroup of predominantly high-grade tumors and in a more 
significant group of distant metastases. The tumors and metastases carrying the 
8q24 amplification frequently over-expressed Ki-67, supporting the hypothesis that 
8q24 amplification contributes to the malignant potential of bladder tumors. Our 
results also indicate that renal tumors having sarcomatoid features display distinct 
expression profiles for the tissue biomarkers Ki-67, gelsolin, and PTEN, when 
compared with profiles in clear-cell and papillary renal tumors. The distinct 
expression profiles in all these tumor types support the hypothesis that renal 
malignancy may develop through various molecular pathways. We also 
demonstrated that in the most common renal malignancy, renal clear-cell 
carcinoma, Ki-67 expression increased with tumor grade and independently 
predicted prognosis, providing further evidence of the prognostic significance of 
Ki-67 expression. 
We studied in detail the expression of gelsolin, an actin-associated protein 
suggested to have tumor suppressing properties in various cancers. Gelsolin 
expression was down-regulated in low-grade renal tumors, showing increasing 
expression with grade. This expression pattern, together with a similar expression 
pattern in bladder cancer, suggests that gelsolin may play multiple roles in cancer 
development and progression. Additionally, increased Ki-67 expression and 
diminished gelsolin expression in individual tumors may indicate poor prognosis in 
grade 2 renal clear-cell carcinoma, suggesting that the molecular signature of renal 
tumors may be useful in prognostication. 
This study shows that urinary tract tumors have distinct expression profiles 
for these biomarkers, and provides evidence that molecular tumor profiling 
utilizing the TMA technique has the capacity to extend our comprehension of the 
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carcinogenic process. Our results also indicate that such expression profiles may be 
useful in predicting clinical outcomes in cancers of the urinary bladder and kidney. 
Based on these results, the TMA technique is an effective screening tool for studies 
of molecular events during carcinogenesis of urinary tract malignancies. 
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